<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>Bloodü©∏Doctor | CLL & Chronic B-cell Disorders</title>
<link rel="preconnect" href="https://fonts.googleapis.com"/>
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin/>
<link href="https://fonts.googleapis.com/css2?family=Fraunces:opsz,wght@9..144,500;9..144,600;9..144,700&family=Source+Sans+3:wght@300;400;500;600;700&family=IBM+Plex+Mono:wght@400;500;600&display=swap" rel="stylesheet"/>
<style>
:root{--bg-ivory:#f7f4ef;--surface:#fff;--ink-deep:#102a43;--ink-body:#243b53;--teal:#006d77;--teal-soft:#83c5be;--amber:#e09f3e;--cranberry:#b23a48;--sage:#2a9d8f;--border:#d9e2ec;--shadow:0 24px 48px rgba(16,42,67,.12);--radius:20px}
*{box-sizing:border-box;margin:0}
html{scroll-behavior:smooth}
body{font-family:'Source Sans 3',system-ui,sans-serif;color:var(--ink-body);background:var(--bg-ivory);line-height:1.6}
h1,h2,h3,h4{font-family:'Fraunces',serif;color:var(--ink-deep)}
a{color:inherit;text-decoration:none}
button{font-family:inherit;cursor:pointer}
code,.mono{font-family:'IBM Plex Mono',monospace}
.page{min-height:100vh}
/* HERO */
.hero{position:relative;padding:40px 6vw 60px;overflow:hidden;background:linear-gradient(135deg,#f7f4ef 0%,#e8f4f3 50%,#f7f4ef 100%)}
.hero::before{content:'';position:absolute;width:500px;height:500px;border-radius:50%;background:radial-gradient(circle,rgba(0,109,119,.18) 0%,transparent 70%);right:-180px;top:-200px}
.hero::after{content:'';position:absolute;width:400px;height:400px;border-radius:50%;background:radial-gradient(circle,rgba(224,159,62,.15) 0%,transparent 70%);left:-120px;bottom:-180px}
.nav{display:flex;align-items:center;justify-content:space-between;position:relative;z-index:1;flex-wrap:wrap;gap:12px}
.brand{font-size:1.5rem;font-weight:700;color:var(--teal)}
.brand-sub{font-size:.85rem;color:var(--ink-body);opacity:.7}
.nav-pills{display:flex;gap:10px;flex-wrap:wrap}
.pill{padding:7px 14px;border-radius:999px;background:rgba(0,109,119,.08);font-size:.82rem;font-weight:600;color:var(--teal)}
.hero-grid{margin-top:48px;display:grid;grid-template-columns:1.2fr 1fr;gap:36px;align-items:center;position:relative;z-index:1}
.hero-copy .tag{display:inline-block;padding:6px 14px;border-radius:999px;background:rgba(0,109,119,.1);font-size:.8rem;font-weight:600;color:var(--teal);margin-bottom:16px}
.hero-copy h1{font-size:clamp(2rem,3.8vw,3.6rem);line-height:1.08;margin-bottom:14px}
.hero-copy p{font-size:1.05rem;color:var(--ink-body);opacity:.78;margin-bottom:24px;max-width:560px}
.cta-row{display:flex;gap:12px;flex-wrap:wrap}
.cta-primary{background:var(--teal);color:#fff;border:none;padding:14px 28px;border-radius:999px;font-weight:600;font-size:.95rem;box-shadow:0 12px 28px rgba(0,109,119,.25);transition:transform .2s,box-shadow .2s}
.cta-primary:hover{transform:translateY(-2px);box-shadow:0 16px 36px rgba(0,109,119,.32)}
.cta-outline{background:transparent;color:var(--teal);border:2px solid var(--teal);padding:12px 24px;border-radius:999px;font-weight:600;font-size:.9rem;transition:all .2s}
.cta-outline:hover{background:var(--teal);color:#fff}
.hero-panel{background:var(--surface);border-radius:var(--radius);padding:24px;box-shadow:var(--shadow)}
.stat-grid{display:grid;gap:12px;margin-top:14px}
.stat{display:flex;justify-content:space-between;padding:12px 14px;border-radius:14px;background:var(--bg-ivory);font-size:.92rem}
.stat strong{color:var(--teal);font-family:'IBM Plex Mono',monospace}
/* STICKY NAV */
.sticky-nav{position:sticky;top:0;z-index:100;background:rgba(247,244,239,.95);backdrop-filter:blur(10px);border-bottom:1px solid var(--border);padding:10px 6vw;display:flex;gap:8px;overflow-x:auto;-webkit-overflow-scrolling:touch}
.sticky-nav a{white-space:nowrap;padding:8px 14px;border-radius:999px;font-size:.82rem;font-weight:600;color:var(--ink-body);transition:all .15s}
.sticky-nav a:hover,.sticky-nav a.active{background:var(--teal);color:#fff}
/* SECTIONS */
.section{padding:56px 6vw}
.section-title{font-size:1.9rem;margin-bottom:10px}
.section-sub{color:var(--ink-body);opacity:.72;max-width:780px;margin-bottom:24px}
/* MODULES */
.module{margin-top:36px;padding:28px;border-radius:var(--radius);background:var(--surface);box-shadow:var(--shadow)}
.module-head{display:flex;justify-content:space-between;align-items:center;flex-wrap:wrap;gap:12px;margin-bottom:18px}
.module-head h3{font-size:1.5rem}
.module-tag{padding:6px 14px;border-radius:999px;font-size:.8rem;font-weight:600}
.tag-dx{background:rgba(0,109,119,.1);color:var(--teal)}
.tag-core{background:rgba(42,157,143,.1);color:var(--sage)}
.tag-mol{background:rgba(224,159,62,.12);color:#b87a20}
.tag-prog{background:rgba(178,58,72,.08);color:var(--cranberry)}
.tag-tx{background:rgba(0,109,119,.1);color:var(--teal)}
.tag-comp{background:rgba(178,58,72,.1);color:var(--cranberry)}
.tag-diff{background:rgba(42,157,143,.1);color:var(--sage)}
.tag-fig{background:rgba(224,159,62,.1);color:#b87a20}
.module-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:18px}
.card{border-radius:16px;padding:18px;background:var(--bg-ivory);display:grid;gap:10px}
.card h4{font-size:1.05rem}
.card p,.card li{color:var(--ink-body);line-height:1.65;font-size:.92rem}
.card ul{padding-left:18px}
.card.deep{background:#f0faf9;border:1px solid rgba(0,109,119,.1)}
/* CALLOUTS */
.callout{margin-top:16px;border-radius:14px;padding:14px 16px;display:grid;gap:6px}
.callout-label{text-transform:uppercase;font-size:.72rem;font-weight:700;letter-spacing:.08em}
.callout-text{font-size:.9rem;line-height:1.6}
.callout.high-yield{background:#fff5e6;border-left:4px solid var(--amber)}
.callout.high-yield .callout-label{color:var(--amber)}
.callout.pitfall{background:#fdf0f1;border-left:4px solid var(--cranberry)}
.callout.pitfall .callout-label{color:var(--cranberry)}
.callout.pearl{background:#e8f7f5;border-left:4px solid var(--sage)}
.callout.pearl .callout-label{color:var(--sage)}
.callout.red-flag{background:#fce8ea;border-left:4px solid #8b1a2b}
.callout.red-flag .callout-label{color:#8b1a2b}
.callout.molecular{background:#ecf9f7;border-left:4px solid var(--teal)}
.callout.molecular .callout-label{color:var(--teal)}
/* TABLES */
.table-wrap{overflow-x:auto;margin-top:10px}
table{width:100%;border-collapse:collapse;font-size:.85rem}
th,td{text-align:left;padding:10px 12px;border-bottom:1px solid var(--border);vertical-align:top}
th{background:rgba(0,109,119,.06);color:var(--ink-deep);font-weight:700;white-space:nowrap}
/* FLOW STEPS */
.flow{display:grid;gap:10px;margin-top:10px}
.flow-step{background:#f3f6f8;border-radius:12px;padding:12px 14px;display:flex;align-items:center;gap:12px;font-size:.9rem}
.flow-num{min-width:28px;height:28px;border-radius:50%;background:var(--teal);color:#fff;display:flex;align-items:center;justify-content:center;font-weight:700;font-size:.85rem}
/* ALGORITHM */
.algo{display:grid;gap:12px;margin-top:14px}
.algo-box{padding:16px;border-radius:14px;text-align:center;font-size:.88rem;font-weight:600}
.algo-decide{background:#fff5e6;border:2px solid var(--amber);color:var(--ink-deep)}
.algo-action{background:#e8f7f5;border:2px solid var(--sage);color:var(--ink-deep)}
.algo-warn{background:#fce8ea;border:2px solid var(--cranberry);color:var(--ink-deep)}
.algo-arrow{text-align:center;font-size:1.4rem;color:var(--teal);font-weight:700}
.algo-row{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:12px}
/* DETAILS */
details{border-radius:14px;border:1px solid var(--border);padding:12px 14px;background:var(--surface);margin-top:12px}
details summary{cursor:pointer;font-weight:600;font-size:.92rem}
details[open] summary{margin-bottom:10px}
/* QUIZ */
.quiz-zone{background:var(--surface);border-radius:var(--radius);padding:28px;box-shadow:var(--shadow);margin-top:36px}
.quiz-tabs{display:flex;gap:8px;margin-bottom:18px}
.quiz-tab{padding:10px 20px;border-radius:999px;border:2px solid var(--teal);background:transparent;color:var(--teal);font-weight:600;font-size:.9rem;transition:all .15s}
.quiz-tab.active{background:var(--teal);color:#fff}
.quiz-progress{height:6px;background:var(--border);border-radius:99px;margin-bottom:18px;overflow:hidden}
.quiz-progress-bar{height:100%;background:var(--teal);border-radius:99px;transition:width .3s}
.q-card{background:var(--bg-ivory);border-radius:16px;padding:20px;margin-bottom:14px}
.q-stem{font-weight:600;font-size:.95rem;margin-bottom:14px;line-height:1.5}
.q-meta{display:flex;gap:8px;margin-bottom:10px;flex-wrap:wrap}
.q-meta span{font-size:.72rem;padding:4px 10px;border-radius:999px;font-weight:600}
.q-topic{background:rgba(0,109,119,.1);color:var(--teal)}
.q-diff-easy{background:rgba(42,157,143,.1);color:var(--sage)}
.q-diff-medium{background:rgba(224,159,62,.12);color:#b87a20}
.q-diff-hard{background:rgba(178,58,72,.1);color:var(--cranberry)}
.q-options{display:grid;gap:8px}
.q-opt{display:flex;align-items:flex-start;gap:10px;padding:12px 14px;border-radius:12px;border:2px solid var(--border);background:var(--surface);cursor:pointer;font-size:.9rem;transition:all .15s;text-align:left;width:100%}
.q-opt:hover:not(.answered){border-color:var(--teal);background:rgba(0,109,119,.03)}
.q-opt.selected{border-color:var(--teal);background:rgba(0,109,119,.05)}
.q-opt.correct{border-color:var(--sage);background:rgba(42,157,143,.08)}
.q-opt.incorrect{border-color:var(--cranberry);background:rgba(178,58,72,.06)}
.q-opt.answered{cursor:default}
.q-opt-letter{min-width:28px;height:28px;border-radius:50%;background:var(--border);display:flex;align-items:center;justify-content:center;font-weight:700;font-size:.8rem;flex-shrink:0}
.q-feedback{margin-top:12px;padding:14px;border-radius:12px;font-size:.88rem;line-height:1.55;display:none}
.q-feedback.show{display:block}
.q-feedback.correct-fb{background:rgba(42,157,143,.08);border:1px solid var(--sage)}
.q-feedback.incorrect-fb{background:rgba(178,58,72,.06);border:1px solid var(--cranberry)}
/* RESULTS */
.results-card{background:var(--surface);border-radius:var(--radius);padding:28px;box-shadow:var(--shadow);text-align:center;display:none}
.results-card.show{display:block}
.results-score{font-size:3rem;font-weight:700;font-family:'Fraunces',serif;color:var(--teal)}
.results-award{font-size:1.5rem;margin:10px 0}
.results-grid{display:grid;grid-template-columns:repeat(5,1fr);gap:14px;margin:20px 0}
.results-stat{padding:14px;border-radius:14px;background:var(--bg-ivory)}
.results-stat .label{font-size:.78rem;color:var(--ink-body);opacity:.7}
.results-stat .value{font-size:1.4rem;font-weight:700;color:var(--teal);font-family:'IBM Plex Mono',monospace}
/* FOOTER */
.footer{padding:28px 6vw 40px;background:var(--ink-deep);color:rgba(255,255,255,.75);display:flex;justify-content:space-between;flex-wrap:wrap;gap:12px;font-size:.85rem}
.footer a{color:var(--teal-soft)}
/* UTILITY */
.simplify .deep,.simplify details,.simplify .table-wrap{display:none}
.hidden{display:none!important}
/* RESPONSIVE */
@media(max-width:980px){.hero-grid,.module-grid{grid-template-columns:1fr}.results-grid{grid-template-columns:repeat(3,1fr)}}
@media(max-width:600px){.results-grid{grid-template-columns:repeat(2,1fr)}}
@media(max-width:720px){.hero{padding:30px 5vw 48px}.section{padding:40px 5vw}.nav{flex-direction:column;align-items:flex-start}}
/* REDUCED MOTION */
@media(prefers-reduced-motion:reduce){*{animation:none!important;transition:none!important}}
/* FADE IN */
@keyframes fadeUp{from{opacity:0;transform:translateY(18px)}to{opacity:1;transform:translateY(0)}}
.module{animation:fadeUp .5s ease both}
/* ===== SVG ALGORITHM STYLES ===== */
.algo-flow{margin-top:24px;padding:28px;border-radius:20px;background:linear-gradient(135deg,#f7f4ef 0%,#e8f4f3 50%,#f7f4ef 100%);border:2px solid var(--border);position:relative;overflow-x:auto}
.algo-flow.algo-warn-bg{background:linear-gradient(135deg,#f7f4ef 0%,#fdf0f1 50%,#f7f4ef 100%)}
.algo-header{display:flex;align-items:center;gap:12px;margin-bottom:28px}
.algo-num{width:44px;height:44px;border-radius:50%;display:flex;align-items:center;justify-content:center;flex-shrink:0}
.algo-num span{color:#fff;font-size:1.3rem;font-weight:700}
.algo-header h4{font-size:1.25rem;margin:0;color:var(--ink-deep);font-family:'Fraunces',serif}
.algo-header .algo-credit{font-size:.78rem;color:var(--ink-body);opacity:.7}
.algo-svg-wrap{display:flex;justify-content:center;width:100%;overflow-x:auto;-webkit-overflow-scrolling:touch}
.algo-svg-wrap svg{display:block;max-width:100%;height:auto}
.algo-svg-wrap svg text{font-family:'Source Sans 3',system-ui,sans-serif}
/* ===== ACTIONABLE ELEMENTS ===== */
.test-yourself{margin-top:18px;border:2px dashed var(--teal);border-radius:16px;padding:18px;background:rgba(0,109,119,.02)}
.test-yourself summary{font-weight:700;font-size:1rem;color:var(--teal);cursor:pointer;display:flex;align-items:center;gap:8px}
.test-yourself summary::before{content:'üß†';font-size:1.1rem}
.test-yourself[open] summary{margin-bottom:14px;padding-bottom:10px;border-bottom:1px solid var(--border)}
.mini-q{background:var(--bg-ivory);border-radius:12px;padding:14px;margin-top:10px}
.mini-q .mini-q-stem{font-weight:600;font-size:.92rem;margin-bottom:10px;line-height:1.5}
.mini-q .mini-q-reveal{margin-top:10px;padding:12px;border-radius:10px;background:#e8f7f5;border:1px solid var(--sage);font-size:.88rem;line-height:1.6}
.mini-q .mini-q-reveal summary{font-weight:600;color:var(--sage);cursor:pointer}
.dx-checklist{list-style:none;padding:0;margin:10px 0}
.dx-checklist li{display:flex;align-items:flex-start;gap:10px;padding:8px 0;border-bottom:1px solid rgba(0,0,0,.04);font-size:.9rem}
.dx-checklist li:last-child{border-bottom:none}
.dx-checklist input[type="checkbox"]{accent-color:var(--teal);width:18px;height:18px;flex-shrink:0;margin-top:2px;cursor:pointer}
.clinical-action{margin-top:14px;border-radius:14px;padding:14px 16px;background:rgba(0,109,119,.04);border:2px solid var(--teal);display:flex;align-items:flex-start;gap:12px}
.clinical-action::before{content:'‚ö°';font-size:1.2rem;flex-shrink:0}
.clinical-action-text{font-size:.88rem;line-height:1.6}
.clinical-action-text strong{color:var(--teal)}
.key-fact{margin-top:10px}
.key-fact summary{font-weight:600;color:var(--teal);font-size:.9rem;cursor:pointer;padding:8px 12px;background:rgba(0,109,119,.04);border-radius:10px;transition:background .15s}
.key-fact summary:hover{background:rgba(0,109,119,.08)}
.key-fact[open] summary{border-radius:10px 10px 0 0;margin-bottom:0}
.key-fact .key-fact-content{padding:12px;background:var(--surface);border:1px solid var(--border);border-top:none;border-radius:0 0 10px 10px;font-size:.88rem;line-height:1.65}
/* ===== DISORDER CARDS (MODULE 7) ===== */
.disorder-card{border-radius:18px;background:var(--surface);border:2px solid var(--border);overflow:hidden;margin-bottom:18px;transition:border-color .2s}
.disorder-card:hover{border-color:var(--teal-soft)}
.disorder-header{padding:18px 20px;background:linear-gradient(135deg,rgba(0,109,119,.06),rgba(42,157,143,.04));cursor:pointer;display:flex;justify-content:space-between;align-items:center;gap:12px}
.disorder-header h4{font-size:1.15rem;margin:0;color:var(--ink-deep)}
.disorder-header .disorder-badge{padding:4px 12px;border-radius:999px;font-size:.72rem;font-weight:700;text-transform:uppercase;letter-spacing:.05em}
.disorder-body{padding:20px}
.disorder-body .disorder-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:14px}
@media(max-width:800px){.disorder-body .disorder-grid{grid-template-columns:1fr}}
.disorder-section{background:var(--bg-ivory);border-radius:14px;padding:16px}
.disorder-section h5{font-size:.95rem;color:var(--teal);margin-bottom:8px;font-family:'Fraunces',serif}
.disorder-section ul{padding-left:16px;font-size:.88rem;line-height:1.7}
.disorder-section p{font-size:.88rem;line-height:1.65}
.compare-table{width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:.82rem;margin-top:12px}
.compare-table th{background:var(--teal);color:#fff;padding:10px 12px;font-weight:600;text-align:left}
.compare-table td{padding:8px 12px;border-bottom:1px solid var(--border);background:var(--surface)}
.compare-table tr:nth-child(even) td{background:var(--bg-ivory)}
.compare-table tr:last-child td{border-bottom:none}
/* PROGRESS TRACKER */
.progress-tracker{display:flex;gap:6px;flex-wrap:wrap;margin-bottom:20px;padding:12px 16px;background:var(--surface);border-radius:14px;box-shadow:0 2px 8px rgba(0,0,0,.04)}
.progress-tracker .pt-item{padding:6px 12px;border-radius:999px;font-size:.78rem;font-weight:600;background:var(--bg-ivory);color:var(--ink-body);transition:all .2s;cursor:pointer;border:2px solid transparent}
.progress-tracker .pt-item:hover{border-color:var(--teal-soft)}
.progress-tracker .pt-item.pt-done{background:rgba(42,157,143,.1);color:var(--sage);border-color:var(--sage)}
</style>
</head>
<body>
<div class="page" id="top">

<!-- HERO -->
<header class="hero">
<nav class="nav">
<div><div class="brand">Bloodü©∏Doctor</div><div class="brand-sub">By Dr Abdul Mannan FRCPath FCPS</div></div>
<div class="nav-pills">
<span class="pill">CLL Learning Hub</span>
<span class="pill">blooddoctor.co@gmail.com</span>
</div>
</nav>
<div class="hero-grid">
<div class="hero-copy">
<div class="tag">Chronic B-cell Disorders &middot; Interactive Learning</div>
<h1>Chronic Lymphocytic Leukaemia and Chronic B-cell Lymphoproliferative Disorders</h1>
<p>High-yield diagnosis, risk stratification, and treatment pathways for trainees. Master CLL and its mimics with structured modules and exam-grade assessments.</p>
<div class="cta-row">
<button class="cta-primary" onclick="document.getElementById('mod-overview').scrollIntoView({behavior:'smooth'})">Start Learning</button>
<button class="cta-outline" onclick="document.getElementById('quiz-zone').scrollIntoView({behavior:'smooth'})">Take MCQ Challenge</button>
<button class="cta-outline" onclick="startEMQ()">Take EMQ Challenge</button>
</div>
</div>
<div class="hero-panel">
<div style="font-weight:700;font-size:1.1rem;color:var(--ink-deep)">Quick metrics</div>
<div class="stat-grid">
<div class="stat"><span>Exam-grade questions</span><strong>65</strong></div>
<div class="stat"><span>Clinical algorithms</span><strong>3</strong></div>
<div class="stat"><span>High-yield tables</span><strong>8+</strong></div>
<div class="stat"><span>Differential disorders</span><strong>7</strong></div>
</div>
</div>
</div>
</header>

<!-- STICKY NAV -->
<nav class="sticky-nav" id="stickyNav">
<a href="#mod-overview">Overview</a>
<a href="#mod-dx">Diagnosis</a>
<a href="#mod-mol">Molecular</a>
<a href="#mod-prog">Prognosis</a>
<a href="#mod-tx">Treatment</a>
<a href="#mod-comp">Complications</a>
<a href="#mod-other">Other Disorders</a>
<a href="#quiz-zone">Quiz Zone</a>
<a href="#mod-bib">Bibliography</a>
</nav>

<main class="section" id="app">

<!-- CONTROLS -->
<div style="display:flex;gap:14px;align-items:center;flex-wrap:wrap;background:var(--surface);border-radius:14px;padding:14px 16px;box-shadow:var(--shadow);margin-bottom:28px">
<strong>Controls</strong>
<button class="cta-outline" style="padding:8px 16px;font-size:.82rem" id="simplifyToggle" onclick="document.getElementById('app').classList.toggle('simplify');this.textContent=this.textContent==='Simplify view'?'Full view':'Simplify view'">Simplify view</button>
<input style="flex:1;min-width:200px;border:1px solid var(--border);border-radius:999px;padding:10px 14px;font-size:.88rem" id="searchBox" placeholder="Search modules by keyword..." oninput="filterModules(this.value)"/>
</div>

<!-- PROGRESS TRACKER -->
<div class="progress-tracker" id="progressTracker">
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 1: Classification</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 2: CLL Core</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 3: Molecular</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 4: Prognosis</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 5: Treatment</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 6: Complications</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Module 7: Other Disorders</span>
<span class="pt-item" onclick="this.classList.toggle('pt-done')">Quiz Zone</span>
</div>

<!-- MODULE 1: OVERVIEW / CLASSIFICATION -->
<section class="module" id="mod-overview">
<div class="module-head"><h3>Module 1: Classification & Diagnostic Approach</h3><span class="module-tag tag-dx">Diagnosis</span></div>
<div class="module-grid">
<div class="card">
<h4>Chronic B-cell Disorders with Leukaemic Expression</h4>
<ul>
<li><strong>CLL / SLL / MBL</strong> &mdash; the CLL spectrum</li>
<li><strong>SMZL</strong> &mdash; Splenic marginal zone lymphoma</li>
<li><strong>HCL</strong> &mdash; Hairy-cell leukaemia</li>
<li><strong>Splenic B-cell lymphoma/leukaemia with prominent nucleoli</strong> (historically HCL variant)</li>
<li><strong>Non-nodal leukaemic MCL</strong> &mdash; Mantle cell lymphoma</li>
<li><strong>LPL / WM</strong> &mdash; Lymphoplasmacytic lymphoma / Waldenstr&ouml;m</li>
<li><strong>SDRPL</strong> &mdash; Splenic diffuse red pulp small B-cell lymphoma</li>
</ul>
</div>
<div class="card">
<h4>Diagnostic Sequence</h4>
<div class="flow">
<div class="flow-step"><span class="flow-num">1</span>Confirm persistent lymphocytosis (&gt;5&times;10<sup>9</sup>/L for &ge;3 months)</div>
<div class="flow-step"><span class="flow-num">2</span>Review blood film morphology with experienced haematopathologist</div>
<div class="flow-step"><span class="flow-num">3</span>Confirm clonality and immunophenotype (B or T, &kappa;/&lambda;)</div>
<div class="flow-step"><span class="flow-num">4</span>Add targeted genetics/FISH where differential exists</div>
<div class="flow-step"><span class="flow-num">5</span>Use tissue biopsy selectively (lymph node, marrow, spleen)</div>
</div>
</div>
</div>
<div class="card deep" style="margin-top:14px">
<h4>Diagnostic Marker Comparison Table</h4>
<div class="table-wrap">
<table>
<thead><tr><th>Disorder</th><th>CD5</th><th>CD23</th><th>CD200</th><th>CD103</th><th>CD123</th><th>Cyclin D1</th><th>MYD88</th><th>BRAF V600E</th></tr></thead>
<tbody>
<tr><td><strong>CLL</strong></td><td>+</td><td>+</td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&plusmn;</td><td>&minus;</td></tr>
<tr><td><strong>SMZL</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>HCL</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+</td><td>+</td><td>weak</td><td>&minus;</td><td>+</td></tr>
<tr><td><strong>Non-nodal MCL</strong></td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>LPL/WM</strong></td><td>&plusmn;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+ (L265P)</td><td>&minus;</td></tr>
<tr><td><strong>SBCL-PN</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&plusmn;</td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>SDRPL</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
</tbody>
</table>
</div>
</div>
<!-- ALGORITHM 1: CLL DIAGNOSTIC ALGORITHM (SVG) -->
<div class="algo-flow">
<div class="algo-header">
<div class="algo-num" style="background:var(--teal)"><span>1</span></div>
<div><h4>CLL Diagnostic Algorithm</h4><div class="algo-credit">Bloodü©∏Doctor &middot; Dr Abdul Mannan FRCPath FCPS</div></div>
</div>
<div class="algo-svg-wrap">
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 800 680" width="800" height="680">
<defs>
<marker id="ah-teal" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#006d77"/></marker>
<marker id="ah-sage" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#2a9d8f"/></marker>
<marker id="ah-cran" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#b23a48"/></marker>
<marker id="ah-amber" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#e09f3e"/></marker>
<marker id="ah-teal-d" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto" markerUnits="strokeWidth"><polygon points="0 0,10 3.5,0 7" fill="#006d77"/></marker>
<filter id="ds"><feDropShadow dx="0" dy="2" stdDeviation="3" flood-opacity=".08"/></filter>
</defs>
<!-- START: Lymphocytosis -->
<rect x="240" y="10" width="320" height="46" rx="14" fill="#fff" stroke="#006d77" stroke-width="2.5" filter="url(#ds)"/>
<text x="400" y="38" text-anchor="middle" font-size="14" font-weight="600" fill="#102a43">Lymphocytosis Detected on FBC</text>
<!-- Arrow down -->
<line x1="400" y1="56" x2="400" y2="86" stroke="#006d77" stroke-width="2.5" marker-end="url(#ah-teal)"/>
<!-- DIAMOND 1: Persistent >3 months? -->
<polygon points="400,90 510,145 400,200 290,145" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds)"/>
<text x="400" y="142" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">Persistent</text>
<text x="400" y="158" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">&gt;3 months?</text>
<!-- NO branch left -->
<line x1="290" y1="145" x2="160" y2="145" stroke="#b23a48" stroke-width="2.5" marker-end="url(#ah-cran)"/>
<rect x="80" y="132" width="20" height="16" rx="8" fill="#b23a48"/><text x="90" y="144" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">NO</text>
<rect x="10" y="165" width="170" height="64" rx="12" fill="rgba(178,58,72,.06)" stroke="#b23a48" stroke-width="2"/>
<text x="95" y="184" text-anchor="middle" font-size="12" font-weight="700" fill="#b23a48">Reactive / Transient</text>
<text x="95" y="200" text-anchor="middle" font-size="10" fill="#243b53">Investigate other causes</text>
<text x="95" y="214" text-anchor="middle" font-size="10" fill="#243b53">(infection, autoimmune, stress)</text>
<!-- YES branch down -->
<line x1="400" y1="200" x2="400" y2="238" stroke="#2a9d8f" stroke-width="2.5" marker-end="url(#ah-sage)"/>
<rect x="380" y="204" width="32" height="16" rx="8" fill="#2a9d8f"/><text x="396" y="216" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">YES</text>
<!-- BOX: Immunophenotyping -->
<rect x="220" y="242" width="360" height="52" rx="14" fill="#fff" stroke="#006d77" stroke-width="2.5" filter="url(#ds)"/>
<text x="400" y="264" text-anchor="middle" font-size="14" font-weight="600" fill="#102a43">Perform Immunophenotyping</text>
<text x="400" y="282" text-anchor="middle" font-size="11" fill="#243b53">(CD5, CD19, CD20, CD23, CD200, SmIg, FMC7)</text>
<!-- Arrow down -->
<line x1="400" y1="294" x2="400" y2="324" stroke="#006d77" stroke-width="2.5" marker-end="url(#ah-teal)"/>
<!-- DIAMOND 2: CLL Score 4-5? -->
<polygon points="400,328 510,383 400,438 290,383" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds)"/>
<text x="400" y="380" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">CLL Score</text>
<text x="400" y="396" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">4‚Äì5?</text>
<!-- LEFT: Score <4 -->
<line x1="290" y1="383" x2="140" y2="383" stroke="#e09f3e" stroke-width="2.5" marker-end="url(#ah-amber)"/>
<rect x="108" y="373" width="52" height="16" rx="8" fill="#e09f3e"/><text x="134" y="385" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">SCORE &lt;4</text>
<rect x="20" y="405" width="240" height="55" rx="12" fill="#fff5e6" stroke="#e09f3e" stroke-width="2"/>
<text x="140" y="424" text-anchor="middle" font-size="12" font-weight="700" fill="#102a43">Consider Other Diagnoses</text>
<text x="140" y="440" text-anchor="middle" font-size="11" fill="#243b53">SMZL, HCL, MCL, LPL/WM</text>
<text x="140" y="452" text-anchor="middle" font-size="10" fill="#243b53">(CD103, BRAF, Cyclin D1, MYD88, Annexin A1)</text>
<!-- RIGHT: Score 4-5 branch down -->
<line x1="400" y1="438" x2="400" y2="468" stroke="#2a9d8f" stroke-width="2.5" marker-end="url(#ah-sage)"/>
<rect x="370" y="442" width="56" height="16" rx="8" fill="#2a9d8f"/><text x="398" y="454" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">SCORE 4‚Äì5</text>
<!-- DIAMOND 3: B cells >=5? -->
<polygon points="400,472 500,517 400,562 300,517" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds)"/>
<text x="400" y="515" text-anchor="middle" font-size="12" font-weight="600" fill="#102a43">B cells</text>
<text x="400" y="530" text-anchor="middle" font-size="12" font-weight="600" fill="#102a43">‚â•5√ó10‚Åπ/L?</text>
<!-- YES = CLL -->
<line x1="350" y1="562" x2="350" y2="598" stroke="#2a9d8f" stroke-width="2.5" marker-end="url(#ah-sage)"/>
<rect x="334" y="564" width="28" height="14" rx="7" fill="#2a9d8f"/><text x="348" y="575" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">YES</text>
<rect x="270" y="602" width="160" height="60" rx="14" fill="#e8f7f5" stroke="#2a9d8f" stroke-width="2.5" filter="url(#ds)"/>
<text x="350" y="626" text-anchor="middle" font-size="16" font-weight="700" fill="#2a9d8f">CLL</text>
<text x="350" y="644" text-anchor="middle" font-size="10" fill="#243b53">Proceed to staging &amp;</text>
<text x="350" y="656" text-anchor="middle" font-size="10" fill="#243b53">molecular workup</text>
<!-- NO = MBL/SLL -->
<line x1="450" y1="562" x2="450" y2="598" stroke="#b23a48" stroke-width="2.5" marker-end="url(#ah-cran)"/>
<rect x="436" y="564" width="24" height="14" rx="7" fill="#b23a48"/><text x="448" y="575" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">NO</text>
<rect x="450" y="602" width="170" height="60" rx="14" fill="rgba(178,58,72,.05)" stroke="#b23a48" stroke-width="2" filter="url(#ds)"/>
<text x="535" y="626" text-anchor="middle" font-size="14" font-weight="700" fill="#102a43">MBL or SLL</text>
<text x="535" y="644" text-anchor="middle" font-size="10" fill="#243b53">Check for tissue disease</text>
<text x="535" y="656" text-anchor="middle" font-size="10" fill="#243b53">(adenopathy, organomegaly)</text>
</svg>
</div>
</div>
<!-- END ALGORITHM 1 -->

<div class="callout pearl"><div class="callout-label">Clinical Pearl</div><div class="callout-text">In typical CLL with high lymphocyte count and classic phenotype, lymph node biopsy is NOT required. Reserve biopsy for atypical cases and suspected lymphoma.</div></div>

<div class="clinical-action">
<div class="clinical-action-text"><strong>Diagnostic Checklist &mdash; CLL Workup:</strong></div>
</div>
<ul class="dx-checklist">
<li><input type="checkbox">FBC with differential &mdash; persistent lymphocytosis &ge;3 months</li>
<li><input type="checkbox">Blood film review with experienced haematopathologist</li>
<li><input type="checkbox">Flow cytometry: CD5, CD19, CD20, CD23, CD200, SmIg, FMC7</li>
<li><input type="checkbox">CLL score calculated (4&ndash;5 supports CLL)</li>
<li><input type="checkbox">Serum immunoglobulins (IgG, IgA, IgM)</li>
<li><input type="checkbox">DAT (baseline, before treatment)</li>
<li><input type="checkbox">Beta-2 microglobulin, LDH</li>
</ul>

<details class="test-yourself">
<summary>Test Yourself &mdash; Module 1</summary>
<div class="mini-q">
<div class="mini-q-stem">A patient has 4.2 &times; 10<sup>9</sup>/L clonal B cells with CLL phenotype (score 5/5), no lymphadenopathy, no organomegaly. Diagnosis?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Monoclonal B-cell Lymphocytosis (MBL).</strong> Clonal B cells &lt;5 &times; 10<sup>9</sup>/L with CLL phenotype but no tissue disease = MBL. High-count MBL progresses at ~1&ndash;2% per year.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">What CLL score marker distinguishes CLL from MCL when both are CD5+?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>CD23 and CD200.</strong> CLL is CD23+/CD200+. MCL is CD23&minus;/CD200&minus;. Also check Cyclin D1 and t(11;14) for MCL.</details>
</div>
</details>
</section>

<!-- MODULE 2: CLL CORE -->
<section class="module" id="mod-core">
<div class="module-head"><h3>Module 2: CLL Core Concepts</h3><span class="module-tag tag-core">Core</span></div>
<div class="module-grid">
<div class="card">
<h4>Definition & CLL-SLL Continuum</h4>
<ul>
<li>CLL: &ge;5&times;10<sup>9</sup>/L monoclonal B cells in blood for &ge;3 months with typical immunophenotype (SmIg<sup>weak</sup>, CD5+, CD19+, CD20<sup>weak</sup>, CD23+, CD200+)</li>
<li>SLL: tissue-dominant disease (same phenotype) with blood B cells &lt;5&times;10<sup>9</sup>/L</li>
<li>MBL: &lt;5&times;10<sup>9</sup>/L clonal B cells, no adenopathy/organomegaly/symptoms</li>
<li>~90% present as CLL, ~10% as SLL</li>
</ul>
</div>
<div class="card">
<h4>Epidemiology & Clinical Features</h4>
<ul>
<li>Most frequent leukaemia in Western countries (~34% of all leukaemias)</li>
<li>M:F ratio 1.5&ndash;2:1; median age at diagnosis ~70 years</li>
<li>~80% diagnosed while asymptomatic (incidental finding)</li>
<li>Painless generalised lymphadenopathy (neck, axillae, inguinal)</li>
<li>Familial risk: 3&ndash;8x higher in first-degree relatives</li>
<li>Rare in Asian populations; remains rare in migrant populations</li>
</ul>
</div>
<div class="card deep">
<h4>Immune Dysfunction Profile</h4>
<ul>
<li><strong>Hypogammaglobulinaemia:</strong> affects ~25%, IgM falls first, then IgG, then IgA</li>
<li><strong>T-cell exhaustion:</strong> inverted CD4/CD8 ratio, increased PD-1/LAG-3/CTLA-4</li>
<li><strong>NK cell / ADCC defects</strong></li>
<li><strong>Monocyte and granulocyte dysfunction</strong></li>
<li><strong>Suboptimal vaccination responses</strong></li>
</ul>
</div>
<div class="card">
<h4>Laboratory Hallmarks</h4>
<ul>
<li>Elevated WBC with absolute lymphocytosis</li>
<li>Small mature lymphocytes with scanty cytoplasm</li>
<li>Smudge cells (Gumprecht cells) on blood film</li>
<li>Prolymphocytes 1&ndash;10% nearly always present when WBC &gt;30&times;10<sup>9</sup>/L</li>
<li>Prolymphocytes &gt;15% = accelerated/transforming CLL</li>
</ul>
</div>
</div>
<div class="callout high-yield"><div class="callout-label">High Yield</div><div class="callout-text">High WBC count alone does NOT mandate treatment in CLL. Treatment is only indicated for active/progressive disease.</div></div>

<details class="test-yourself">
<summary>Test Yourself &mdash; Module 2</summary>
<div class="mini-q">
<div class="mini-q-stem">A CLL patient has prolymphocytes &gt;15% on blood film. What does this signify?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Accelerated / transforming CLL.</strong> Prolymphocytes &gt;15% (formerly called &ldquo;prolymphocytic transformation&rdquo;) signals disease acceleration. Assess for Richter transformation.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">Which immunoglobulin class falls first in CLL-related hypogammaglobulinaemia?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>IgM falls first,</strong> then IgG, then IgA. Hypogammaglobulinaemia affects ~25% and is the major driver of infection susceptibility.</details>
</div>
</details>
</section>

<!-- MODULE 3: MOLECULAR -->
<section class="module" id="mod-mol">
<div class="module-head"><h3>Module 3: Molecular & Cytogenetics Simplified</h3><span class="module-tag tag-mol">High Priority</span></div>
<div class="module-grid">
<div class="card deep">
<h4>IGHV Mutated vs Unmutated</h4>
<p><strong>Two biologic behaviours in one disease.</strong> Mutated IGHV (&lt;98% germline homology) = post-germinal centre origin, indolent biology, longer treatment-free interval, median survival &gt;15 years. Unmutated IGHV = pre-GC origin, aggressive kinetics, shorter survival (6&ndash;7 years historically).</p>
</div>
<div class="card deep">
<h4>del(13q) Isolated</h4>
<p><strong>Generally favourable biology.</strong> Present in 25&ndash;40% of cases. Associated with mutated IGHV, MYD88 mutations, miR-15a/miR-16 involvement. Median survival &gt;15 years when found as sole abnormality.</p>
</div>
<div class="card deep">
<h4>del(11q) / ATM</h4>
<p><strong>Higher-risk profile in CIT era.</strong> Present in 20&ndash;25%. Associated with unmutated IGHV, ATM mutations (30%), BIRC3 mutations. Historically shorter treatment-free survival. BCRi/BCL2i overcome poor prognostic significance.</p>
</div>
<div class="card deep">
<h4>del(17p) / TP53</h4>
<p><strong>Poor CIT response; pathway inhibitor preference.</strong> Present in 5&ndash;50% depending on disease stage. Usually accompanied by TP53 mutation on other allele. The most important predictor of CIT resistance. Must use BTKi or BCL2i. Median survival 3&ndash;6 years with CIT.</p>
</div>
<div class="card deep">
<h4>Complex Karyotype</h4>
<p><strong>Risk escalation marker.</strong> Defined as &gt;3 or &gt;5 aberrations. Found in 5&ndash;30%. Often includes TP53 mutations. Associated with clonal evolution and poorer outcomes even with targeted therapy.</p>
</div>
<div class="card deep">
<h4>BCR Signalling & Apoptosis Escape</h4>
<p><strong>Why BTKi and BCL2i work.</strong> CLL cells depend on BCR signalling for survival and proliferation &rarr; BTK inhibitors block this pathway. CLL cells overexpress BCL2 (antiapoptotic) &rarr; venetoclax directly triggers apoptosis. This explains the class-switch strategy in relapsed disease.</p>
</div>
</div>
<details>
<summary>Cytogenetic Correlation Table (Table 23.3)</summary>
<div class="table-wrap">
<table>
<thead><tr><th>Abnormality</th><th>Frequency</th><th>Biological</th><th>Clinical</th><th>Median Survival</th></tr></thead>
<tbody>
<tr><td>del(13q14) isolated</td><td>25&ndash;40%</td><td>Mutated IGHV, MYD88, miR15/16</td><td>Good prognosis</td><td>&gt;15 years</td></tr>
<tr><td>Trisomy 12</td><td>15&ndash;20%</td><td>Unmutated IGHV, NOTCH1, atypical morphology</td><td>Short treatment-free survival after CIT</td><td>~10 years</td></tr>
<tr><td>del(11q22-23)</td><td>20&ndash;25%</td><td>Unmutated IGHV, ATM/BIRC3 mutations</td><td>Short TFS; BCRi/BCL2i overcome</td><td>6&ndash;8 years</td></tr>
<tr><td>del(17p13.1)</td><td>5&ndash;50%</td><td>Unmutated IGHV, TP53, complex karyotype</td><td>CIT resistance; use pathway inhibitors</td><td>3&ndash;6 years</td></tr>
</tbody>
</table>
</div>
</details>
<div class="callout molecular"><div class="callout-label">Molecular Simplified</div><div class="callout-text">Think of IGHV status as the master switch: mutated = slow lane, unmutated = fast lane. TP53/del(17p) = CIT exit ramp &rarr; must use BTKi or BCL2i.</div></div>

<div class="clinical-action">
<div class="clinical-action-text"><strong>Pre-Treatment Molecular Workup Checklist:</strong></div>
</div>
<ul class="dx-checklist">
<li><input type="checkbox">FISH panel: del(13q), trisomy 12, del(11q), del(17p)</li>
<li><input type="checkbox">TP53 mutation status by NGS (mandatory before any therapy)</li>
<li><input type="checkbox">IGHV mutation status</li>
<li><input type="checkbox">Complex karyotype assessment (stimulated metaphase)</li>
</ul>

<details class="test-yourself">
<summary>Test Yourself &mdash; Module 3</summary>
<div class="mini-q">
<div class="mini-q-stem">A CLL patient has del(17p) on FISH and TP53 mutation on NGS. They are young and fit. Can you give them FCR?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>No.</strong> TP53/del(17p) disruption predicts CIT resistance. Must use pathway inhibitors: BTKi (zanubrutinib/acalabrutinib) or venetoclax + anti-CD20. FCR will produce short-lived, poor-quality responses.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">Why do CLL cells overexpress BCL2 and why does this matter therapeutically?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>BCL2 is an anti-apoptotic protein.</strong> CLL cells depend on it for survival. <strong>Venetoclax</strong> is a BH3-mimetic that directly inhibits BCL2, triggering apoptosis. This explains why it works even in TP53-disrupted disease (apoptosis independent of p53).</details>
</div>
</details>
</section>

<!-- MODULE 4: PROGNOSIS -->
<section class="module" id="mod-prog">
<div class="module-head"><h3>Module 4: Prognosis & Risk Stratification</h3><span class="module-tag tag-prog">Prognosis</span></div>
<div class="module-grid">
<div class="card deep">
<h4>Rai Staging</h4>
<div class="table-wrap">
<table>
<thead><tr><th>Stage</th><th>Features</th><th>Risk</th><th>Median Survival</th></tr></thead>
<tbody>
<tr><td>0</td><td>Lymphocytosis only</td><td>Low</td><td>&gt;15 years</td></tr>
<tr><td>I</td><td>+ Lymphadenopathy</td><td>Intermediate</td><td>~10 years</td></tr>
<tr><td>II</td><td>+ Spleen/liver enlargement</td><td>Intermediate</td><td>7&ndash;9 years</td></tr>
<tr><td>III</td><td>+ Anaemia (Hb &lt;110 g/L)</td><td>High</td><td>3&ndash;5 years</td></tr>
<tr><td>IV</td><td>+ Thrombocytopenia (&lt;100&times;10<sup>9</sup>/L)</td><td>High</td><td>3&ndash;5 years</td></tr>
</tbody>
</table>
</div>
</div>
<div class="card deep">
<h4>Binet Staging</h4>
<div class="table-wrap">
<table>
<thead><tr><th>Stage</th><th>Features</th><th>Median Survival</th></tr></thead>
<tbody>
<tr><td>A</td><td>&lt;3 lymphoid areas enlarged</td><td>&gt;15 years</td></tr>
<tr><td>B</td><td>&ge;3 lymphoid areas enlarged</td><td>7&ndash;9 years</td></tr>
<tr><td>C</td><td>Hb &lt;110 g/L and/or platelets &lt;100&times;10<sup>9</sup>/L</td><td>3&ndash;5 years</td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="module-grid" style="margin-top:14px">
<div class="card" style="background:#e8f7f5;border:2px solid var(--sage)">
<h4 style="color:var(--sage)">Good-Risk Pattern</h4>
<ul>
<li>Early stage (Binet A, Rai 0)</li>
<li>Mutated IGHV</li>
<li>Isolated del(13q)</li>
<li>Normal beta-2 microglobulin</li>
<li>Low blood lymphocyte count (&lt;15&times;10<sup>9</sup>/L)</li>
<li>Long LDT (&gt;12 months)</li>
</ul>
</div>
<div class="card" style="background:#fce8ea;border:2px solid var(--cranberry)">
<h4 style="color:var(--cranberry)">High-Risk Pattern</h4>
<ul>
<li>Advanced stage (Binet B/C, Rai I&ndash;IV)</li>
<li>Unmutated IGHV</li>
<li>del(17p)/TP53, del(11q), complex karyotype</li>
<li>Elevated beta-2 microglobulin</li>
<li>High blood lymphocyte count (&ge;15&times;10<sup>9</sup>/L)</li>
<li>Short LDT (&lt;12 months)</li>
</ul>
</div>
</div>
<div class="callout pearl"><div class="callout-label">Clinical Pearl</div><div class="callout-text">The CLL-IPI combines Rai stage, age, TP53, IGHV status and beta-2 microglobulin into four risk groups. However, it was developed for CIT-treated patients and poorly predicts outcomes on BTKi/BCL2i.</div></div>

<details class="test-yourself">
<summary>Test Yourself &mdash; Module 4</summary>
<div class="mini-q">
<div class="mini-q-stem">A patient has Hb 95 g/L from marrow failure and platelets 85 &times; 10<sup>9</sup>/L. What is their Rai stage?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Rai Stage IV (High Risk).</strong> Stage III = anaemia (Hb &lt;110 g/L) from marrow failure. Stage IV = thrombocytopenia (&lt;100 &times; 10<sup>9</sup>/L). Having both makes it Stage IV. Median survival 3&ndash;5 years historically.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">Patient has Binet A with mutated IGHV, isolated del(13q), normal beta-2 microglobulin. Prognosis?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Excellent prognosis.</strong> All favourable markers: early stage, mutated IGHV, isolated del(13q), normal beta-2M. Median survival &gt;15 years. Many patients never require treatment.</details>
</div>
</details>
</section>

<!-- MODULE 5: TREATMENT -->
<section class="module" id="mod-tx">
<div class="module-head"><h3>Module 5: Treatment Strategy</h3><span class="module-tag tag-tx">Treatment</span></div>
<div class="module-grid">
<div class="card">
<h4>When NOT to Treat: Active Surveillance</h4>
<p>Asymptomatic early-stage CLL (Binet A, Rai 0) without active disease features should be observed with periodic monitoring. Early treatment has NOT shown survival benefit.</p>
</div>
<div class="card">
<h4>Treatment Initiation Criteria</h4>
<ul>
<li>Hb &lt;110 g/L from marrow failure</li>
<li>Platelets &lt;100&times;10<sup>9</sup>/L from marrow failure</li>
<li>Massive (&ge;6 cm below costal margin) or progressive splenomegaly</li>
<li>Massive (&ge;10 cm) or progressive lymphadenopathy</li>
<li>Progressive lymphocytosis (&gt;50% increase in 2 months or LDT &lt;6 months)</li>
<li>Constitutional symptoms (B symptoms)</li>
<li>Refractory autoimmune cytopenia</li>
</ul>
</div>
</div>
<!-- ALGORITHM 2: CLL TREATMENT DECISION (SVG) -->
<div class="algo-flow">
<div class="algo-header">
<div class="algo-num" style="background:var(--teal)"><span>2</span></div>
<div><h4>CLL Treatment Decision Algorithm</h4><div class="algo-credit">Bloodü©∏Doctor &middot; Dr Abdul Mannan FRCPath FCPS</div></div>
</div>
<div class="algo-svg-wrap">
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 860 920" width="860" height="920">
<defs>
<marker id="a2t" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#006d77"/></marker>
<marker id="a2s" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#2a9d8f"/></marker>
<marker id="a2c" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#b23a48"/></marker>
<marker id="a2a" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#e09f3e"/></marker>
<filter id="ds2"><feDropShadow dx="0" dy="2" stdDeviation="3" flood-opacity=".08"/></filter>
</defs>
<!-- START -->
<rect x="310" y="10" width="240" height="44" rx="14" fill="#fff" stroke="#006d77" stroke-width="2.5" filter="url(#ds2)"/>
<text x="430" y="37" text-anchor="middle" font-size="15" font-weight="700" fill="#006d77">CLL Diagnosed</text>
<line x1="430" y1="54" x2="430" y2="82" stroke="#006d77" stroke-width="2.5" marker-end="url(#a2t)"/>
<!-- DIAMOND: Active disease? -->
<polygon points="430,86 540,141 430,196 320,141" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds2)"/>
<text x="430" y="137" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">Active Disease</text>
<text x="430" y="153" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">Criteria Met?</text>
<!-- NO branch left -->
<line x1="320" y1="141" x2="180" y2="141" stroke="#2a9d8f" stroke-width="2.5" marker-end="url(#a2s)"/>
<rect x="196" y="131" width="24" height="14" rx="7" fill="#2a9d8f"/><text x="208" y="142" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">NO</text>
<rect x="20" y="114" width="160" height="64" rx="14" fill="#e8f7f5" stroke="#2a9d8f" stroke-width="2.5" filter="url(#ds2)"/>
<text x="100" y="138" text-anchor="middle" font-size="14" font-weight="700" fill="#2a9d8f">Watch &amp; Wait</text>
<text x="100" y="154" text-anchor="middle" font-size="10" fill="#243b53">Monitor every 3‚Äì6 months</text>
<text x="100" y="168" text-anchor="middle" font-size="10" fill="#243b53">FBC, clinical exam, LDT</text>
<!-- YES down -->
<line x1="430" y1="196" x2="430" y2="224" stroke="#e09f3e" stroke-width="2.5" marker-end="url(#a2a)"/>
<rect x="414" y="200" width="28" height="14" rx="7" fill="#e09f3e"/><text x="428" y="211" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">YES</text>
<!-- Assess Biomarkers -->
<rect x="230" y="228" width="400" height="44" rx="14" fill="#fff" stroke="#006d77" stroke-width="2.5" filter="url(#ds2)"/>
<text x="430" y="255" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">Assess TP53/del(17p) + IGHV Status + Patient Fitness</text>
<line x1="430" y1="272" x2="430" y2="300" stroke="#006d77" stroke-width="2.5" marker-end="url(#a2t)"/>
<!-- DIAMOND: TP53? -->
<polygon points="430,304 540,359 430,414 320,359" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds2)"/>
<text x="430" y="355" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">del(17p)/TP53</text>
<text x="430" y="371" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">Disrupted?</text>
<!-- THREE COLUMNS from diamond -->
<!-- COL 1: YES TP53 - left -->
<line x1="320" y1="359" x2="155" y2="359" stroke="#b23a48" stroke-width="2" />
<line x1="155" y1="359" x2="155" y2="428" stroke="#b23a48" stroke-width="2" marker-end="url(#a2c)"/>
<rect x="92" y="348" width="110" height="16" rx="8" fill="#b23a48"/><text x="147" y="360" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">YES ‚Äî TP53 DISRUPTED</text>
<rect x="40" y="432" width="230" height="168" rx="14" fill="#fce8ea" stroke="#b23a48" stroke-width="2.5" filter="url(#ds2)"/>
<text x="155" y="452" text-anchor="middle" font-size="10" font-weight="700" fill="#b23a48" letter-spacing=".5">HIGH RISK</text>
<text x="155" y="472" text-anchor="middle" font-size="14" font-weight="700" fill="#b23a48">BTKi Preferred</text>
<text x="155" y="490" text-anchor="middle" font-size="11" fill="#243b53">Zanubrutinib or Acalabrutinib</text>
<text x="155" y="504" text-anchor="middle" font-size="10" fill="#243b53">(2nd-gen preferred over ibrutinib)</text>
<line x1="80" y1="516" x2="230" y2="516" stroke="#b23a48" stroke-width="1" stroke-dasharray="4 3"/>
<text x="155" y="530" text-anchor="middle" font-size="11" font-weight="600" fill="#102a43">OR Venetoclax + anti-CD20</text>
<rect x="62" y="542" width="186" height="30" rx="8" fill="rgba(178,58,72,.08)"/>
<text x="155" y="556" text-anchor="middle" font-size="10" fill="#b23a48" font-weight="600">Avoid CIT ‚Äî resistance expected</text>
<text x="155" y="592" text-anchor="middle" font-size="10" fill="#243b53" font-style="italic">MRD-guided; continuous BTKi</text>
<!-- COL 2: IGHV Mutated - center -->
<line x1="430" y1="414" x2="430" y2="428" stroke="#2a9d8f" stroke-width="2.5" marker-end="url(#a2s)"/>
<rect x="380" y="416" width="100" height="16" rx="8" fill="#2a9d8f"/><text x="430" y="428" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">NO + IGHV MUTATED</text>
<rect x="315" y="432" width="230" height="168" rx="14" fill="#e8f7f5" stroke="#2a9d8f" stroke-width="2.5" filter="url(#ds2)"/>
<text x="430" y="452" text-anchor="middle" font-size="10" font-weight="700" fill="#2a9d8f" letter-spacing=".5">FAVOURABLE</text>
<text x="430" y="472" text-anchor="middle" font-size="14" font-weight="700" fill="#2a9d8f">Consider FCR</text>
<text x="430" y="490" text-anchor="middle" font-size="11" fill="#243b53">Fit patients &lt;65 years</text>
<text x="430" y="504" text-anchor="middle" font-size="10" fill="#243b53">(curative potential in this subset)</text>
<line x1="350" y1="516" x2="510" y2="516" stroke="#2a9d8f" stroke-width="1" stroke-dasharray="4 3"/>
<text x="430" y="530" text-anchor="middle" font-size="11" font-weight="600" fill="#102a43">OR BTKi / Ven + Obinutuzumab</text>
<rect x="337" y="542" width="186" height="30" rx="8" fill="rgba(42,157,143,.06)"/>
<text x="430" y="556" text-anchor="middle" font-size="10" fill="#2a9d8f" font-weight="600">Equally effective if not fit for FCR</text>
<text x="430" y="592" text-anchor="middle" font-size="10" fill="#243b53" font-style="italic">Fixed-duration preferred</text>
<!-- COL 3: IGHV Unmutated - right -->
<line x1="540" y1="359" x2="705" y2="359" stroke="#e09f3e" stroke-width="2"/>
<line x1="705" y1="359" x2="705" y2="428" stroke="#e09f3e" stroke-width="2" marker-end="url(#a2a)"/>
<rect x="634" y="348" width="120" height="16" rx="8" fill="#e09f3e"/><text x="694" y="360" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">NO + IGHV UNMUTATED</text>
<rect x="590" y="432" width="230" height="168" rx="14" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds2)"/>
<text x="705" y="452" text-anchor="middle" font-size="10" font-weight="700" fill="#b87a20" letter-spacing=".5">INTERMEDIATE RISK</text>
<text x="705" y="472" text-anchor="middle" font-size="13" font-weight="700" fill="#b87a20">BTKi or Ven+Obi</text>
<text x="705" y="490" text-anchor="middle" font-size="11" fill="#243b53">Pathway inhibitors preferred</text>
<text x="705" y="504" text-anchor="middle" font-size="10" fill="#243b53">over CIT in unmutated IGHV</text>
<rect x="612" y="518" width="186" height="30" rx="8" fill="rgba(224,159,62,.08)"/>
<text x="705" y="532" text-anchor="middle" font-size="10" fill="#b87a20" font-weight="600">Avoid FCR ‚Äî short remissions</text>
<text x="705" y="562" text-anchor="middle" font-size="10" fill="#243b53" font-style="italic">Continuous or fixed-duration</text>
<!-- FRAIL callout -->
<rect x="160" y="618" width="540" height="44" rx="14" fill="rgba(178,58,72,.04)" stroke="#b23a48" stroke-width="2" stroke-dasharray="6 4"/>
<text x="180" y="636" font-size="12" font-weight="700" fill="#b23a48">!</text>
<text x="200" y="636" font-size="12" font-weight="700" fill="#b23a48">Frail / Elderly:</text>
<text x="200" y="652" font-size="11" fill="#243b53">Chlorambucil+Obinutuzumab or low-dose ibrutinib. Ven+Obi with TLS monitoring.</text>
<!-- SEPARATOR -->
<line x1="230" y1="682" x2="630" y2="682" stroke="#006d77" stroke-width="1.5" opacity=".3"/>
<text x="430" y="700" text-anchor="middle" font-size="11" font-weight="700" fill="#006d77" letter-spacing="1.5">RELAPSED / REFRACTORY</text>
<line x1="430" y1="706" x2="430" y2="730" stroke="#006d77" stroke-width="2.5" marker-end="url(#a2t)"/>
<!-- DIAMOND: Prior therapy -->
<polygon points="430,734 520,774 430,814 340,774" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds2)"/>
<text x="430" y="772" text-anchor="middle" font-size="12" font-weight="600" fill="#102a43">What Was</text>
<text x="430" y="786" text-anchor="middle" font-size="12" font-weight="600" fill="#102a43">Prior Therapy?</text>
<!-- After BTKi -->
<line x1="340" y1="774" x2="155" y2="774" stroke="#2a9d8f" stroke-width="2"/>
<line x1="155" y1="774" x2="155" y2="834" stroke="#2a9d8f" stroke-width="2" marker-end="url(#a2s)"/>
<rect x="108" y="764" width="62" height="14" rx="7" fill="#2a9d8f"/><text x="139" y="775" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">AFTER BTKi</text>
<rect x="55" y="838" width="200" height="54" rx="12" fill="#e8f7f5" stroke="#2a9d8f" stroke-width="2"/>
<text x="155" y="858" text-anchor="middle" font-size="12" font-weight="700" fill="#2a9d8f">Switch to Venetoclax</text>
<text x="155" y="876" text-anchor="middle" font-size="10" fill="#243b53">Venetoclax + Rituximab (fixed)</text>
<!-- After BCL2i -->
<line x1="430" y1="814" x2="430" y2="834" stroke="#2a9d8f" stroke-width="2.5" marker-end="url(#a2s)"/>
<rect x="385" y="816" width="62" height="14" rx="7" fill="#2a9d8f"/><text x="416" y="827" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">AFTER BCL2i</text>
<rect x="330" y="838" width="200" height="54" rx="12" fill="#e8f7f5" stroke="#2a9d8f" stroke-width="2"/>
<text x="430" y="858" text-anchor="middle" font-size="12" font-weight="700" fill="#2a9d8f">Switch to BTKi</text>
<text x="430" y="876" text-anchor="middle" font-size="10" fill="#243b53">Zanubrutinib / Acalabrutinib</text>
<!-- Multi-refractory -->
<line x1="520" y1="774" x2="705" y2="774" stroke="#b23a48" stroke-width="2"/>
<line x1="705" y1="774" x2="705" y2="834" stroke="#b23a48" stroke-width="2" marker-end="url(#a2c)"/>
<rect x="636" y="764" width="90" height="14" rx="7" fill="#b23a48"/><text x="681" y="775" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">MULTI-REFRACTORY</text>
<rect x="605" y="838" width="200" height="68" rx="12" fill="#fce8ea" stroke="#b23a48" stroke-width="2.5"/>
<text x="705" y="858" text-anchor="middle" font-size="12" font-weight="700" fill="#b23a48">Allo-HSCT / CAR-T</text>
<text x="705" y="876" text-anchor="middle" font-size="10" fill="#243b53">Clinical trial evaluation</text>
<text x="705" y="892" text-anchor="middle" font-size="10" fill="#243b53">Pirtobrutinib (non-covalent BTKi)</text>
</svg>
</div>
</div>
<!-- END ALGORITHM 2 -->
<details>
<summary>Key Drug Profiles</summary>
<div class="table-wrap">
<table>
<thead><tr><th>Agent</th><th>Class</th><th>Key Points</th></tr></thead>
<tbody>
<tr><td>Ibrutinib</td><td>BTKi (1st gen)</td><td>Continuous therapy; AF, hypertension, bleeding risk</td></tr>
<tr><td>Acalabrutinib/Zanubrutinib</td><td>BTKi (2nd gen)</td><td>More selective; lower cardiac toxicity</td></tr>
<tr><td>Venetoclax</td><td>BCL2i</td><td>Fixed-duration with anti-CD20; TLS risk &rarr; dose ramp-up required</td></tr>
<tr><td>FCR</td><td>CIT</td><td>Selected fit young patients with mutated IGHV, no TP53; curative potential in subset</td></tr>
</tbody>
</table>
</div>
</details>
<div class="callout pitfall"><div class="callout-label">Pitfall</div><div class="callout-text">Do NOT confuse BTKi redistribution lymphocytosis with disease progression. Rising lymphocyte count with improving nodes/symptoms is an expected pharmacological effect.</div></div>

<div class="clinical-action">
<div class="clinical-action-text"><strong>Treatment Initiation Checklist:</strong></div>
</div>
<ul class="dx-checklist">
<li><input type="checkbox">Active disease criteria confirmed (cytopenias, organomegaly, LDT, B symptoms)</li>
<li><input type="checkbox">TP53/del(17p) status known before starting any therapy</li>
<li><input type="checkbox">IGHV mutation status available</li>
<li><input type="checkbox">Hepatitis B screening (HBsAg, anti-HBs, anti-HBc) before anti-CD20</li>
<li><input type="checkbox">Baseline cardiac assessment if considering BTKi (ECG, BP, AF history)</li>
<li><input type="checkbox">TLS risk assessment if considering venetoclax (tumour burden, renal function, urate)</li>
<li><input type="checkbox">Patient fitness/frailty assessed (CIRS, ECOG)</li>
</ul>

<details class="test-yourself">
<summary>Test Yourself &mdash; Module 5</summary>
<div class="mini-q">
<div class="mini-q-stem">A 58-year-old fit woman with CLL (mutated IGHV, no TP53, Binet C) needs treatment. What is the one regimen with curative potential in this subgroup?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>FCR (Fludarabine, Cyclophosphamide, Rituximab).</strong> In fit patients with mutated IGHV and no TP53, FCR achieves long-term (60%+) remissions &gt;10 years. This is the only CLL context where CIT has curative potential.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">Patient on ibrutinib develops AF. What two drug classes should you AVOID combining with ibrutinib?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Warfarin</strong> (bleeding risk with ibrutinib platelet dysfunction) and <strong>verapamil/diltiazem</strong> (CYP3A4 inhibitors increase ibrutinib levels). Use DOACs cautiously; prefer beta-blockers for rate control.</details>
</div>
</details>
</section>

<!-- MODULE 6: COMPLICATIONS -->
<section class="module" id="mod-comp">
<div class="module-head"><h3>Module 6: Complications & Supportive Care</h3><span class="module-tag tag-comp">Complications</span></div>
<div class="module-grid">
<div class="card">
<h4>Autoimmune Cytopenias</h4>
<ul>
<li><strong>AIHA:</strong> ~10% of CLL patients; elevated LDH, low haptoglobin, positive DAT (IgG/C3)</li>
<li><strong>ITP:</strong> 5&ndash;7%; isolated thrombocytopenia with preserved marrow megakaryocytes</li>
<li><strong>Evans syndrome:</strong> concurrent AIHA + ITP</li>
<li><strong>PRCA:</strong> &lt;1%; low reticulocytes, arrested red cell precursors</li>
<li>Treatment: corticosteroids first &rarr; rituximab &rarr; alternative immunosuppression &rarr; anti-CLL therapy if refractory</li>
</ul>
</div>
<div class="card">
<h4>Infection Risk & Vaccination</h4>
<ul>
<li>Infections are the commonest cause of death (40&ndash;60%)</li>
<li>Multifactorial: low IgG, impaired antigen presentation, treatment toxicity</li>
<li>IgG replacement for profound hypogammaglobulinaemia + recurrent infections</li>
<li>Screen ALL patients for hepatitis B before anti-CD20 therapy</li>
<li>Vaccination: inactivated influenza, pneumococcal, herpes zoster &mdash; response is suboptimal but still recommended</li>
</ul>
</div>
<div class="card deep">
<h4>Richter Transformation</h4>
<ul>
<li>Occurs in ~5% of patients; transformation to DLBCL (most common) or Hodgkin lymphoma</li>
<li><strong>Clonally related (80%):</strong> poor prognosis, median survival &lt;1 year; consider allo-HSCT</li>
<li><strong>Clonally unrelated (20%):</strong> prognosis like de novo DLBCL; treat with R-CHOP</li>
<li>Associated with: unmutated IGHV, NOTCH1, TP53, CDKN2A/B, MYC mutations</li>
<li>PET/CT helps target biopsy to metabolically active sites</li>
</ul>
</div>
<div class="card">
<h4>Second Neoplasias</h4>
<ul>
<li>10&ndash;15% of CLL patients develop other cancers</li>
<li>Melanoma, lung carcinoma, lymphoma, GI tumours most frequent</li>
<li>Substantially increased risk of Merkel cell carcinoma</li>
<li>Secondary MDS/AML in ~5% of heavily pre-treated patients (e.g., post-FCR)</li>
</ul>
</div>
</div>
<!-- ALGORITHM 3: RICHTER TRANSFORMATION WORKUP (SVG) -->
<div class="algo-flow algo-warn-bg">
<div class="algo-header">
<div class="algo-num" style="background:var(--cranberry)"><span>3</span></div>
<div><h4>Richter Transformation Workup Algorithm</h4><div class="algo-credit">Bloodü©∏Doctor &middot; Dr Abdul Mannan FRCPath FCPS</div></div>
</div>
<div class="algo-svg-wrap">
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 720 560" width="720" height="560">
<defs>
<marker id="a3t" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#006d77"/></marker>
<marker id="a3c" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#b23a48"/></marker>
<marker id="a3s" markerWidth="10" markerHeight="7" refX="9" refY="3.5" orient="auto"><polygon points="0 0,10 3.5,0 7" fill="#2a9d8f"/></marker>
<filter id="ds3"><feDropShadow dx="0" dy="2" stdDeviation="3" flood-opacity=".08"/></filter>
</defs>
<!-- Alert -->
<rect x="130" y="10" width="460" height="50" rx="14" fill="#fce8ea" stroke="#b23a48" stroke-width="2.5" filter="url(#ds3)"/>
<text x="160" y="40" font-size="16" fill="#b23a48">&#9888;</text>
<text x="180" y="36" font-size="12" font-weight="700" fill="#b23a48">Clinical Suspicion:</text>
<text x="320" y="36" font-size="12" fill="#102a43">Rapid node growth + Rising LDH + B symptoms</text>
<line x1="360" y1="60" x2="360" y2="88" stroke="#b23a48" stroke-width="2.5" marker-end="url(#a3c)"/>
<!-- PET/CT -->
<rect x="180" y="92" width="360" height="50" rx="14" fill="#fff" stroke="#006d77" stroke-width="2.5" filter="url(#ds3)"/>
<text x="360" y="114" text-anchor="middle" font-size="14" font-weight="600" fill="#102a43">PET/CT Scan</text>
<text x="360" y="130" text-anchor="middle" font-size="10" fill="#243b53">Identify most metabolically active site (SUVmax often &gt;5)</text>
<line x1="360" y1="142" x2="360" y2="170" stroke="#006d77" stroke-width="2.5" marker-end="url(#a3t)"/>
<!-- Biopsy -->
<rect x="180" y="174" width="360" height="50" rx="14" fill="#fff" stroke="#006d77" stroke-width="2.5" filter="url(#ds3)"/>
<text x="360" y="196" text-anchor="middle" font-size="14" font-weight="600" fill="#102a43">PET-Guided Tissue Biopsy</text>
<text x="360" y="212" text-anchor="middle" font-size="10" fill="#243b53">Core/excisional biopsy from hottest node</text>
<line x1="360" y1="224" x2="360" y2="252" stroke="#006d77" stroke-width="2.5" marker-end="url(#a3t)"/>
<!-- Diamond: Clonal? -->
<polygon points="360,256 470,311 360,366 250,311" fill="#fff5e6" stroke="#e09f3e" stroke-width="2.5" filter="url(#ds3)"/>
<text x="360" y="308" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">Clonally related</text>
<text x="360" y="324" text-anchor="middle" font-size="13" font-weight="600" fill="#102a43">to CLL?</text>
<!-- YES left -->
<line x1="250" y1="311" x2="80" y2="311" stroke="#b23a48" stroke-width="2"/>
<line x1="80" y1="311" x2="80" y2="400" stroke="#b23a48" stroke-width="2" marker-end="url(#a3c)"/>
<rect x="98" y="300" width="60" height="16" rx="8" fill="#b23a48"/><text x="128" y="312" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">YES (~80%)</text>
<rect x="10" y="404" width="300" height="140" rx="14" fill="#fce8ea" stroke="#b23a48" stroke-width="2.5" filter="url(#ds3)"/>
<text x="160" y="430" text-anchor="middle" font-size="14" font-weight="700" fill="#b23a48">Clonally Related DLBCL</text>
<line x1="40" y1="440" x2="280" y2="440" stroke="#b23a48" stroke-width=".5"/>
<text x="160" y="460" text-anchor="middle" font-size="11" fill="#243b53">Poor prognosis (median OS &lt;1 year)</text>
<text x="160" y="478" text-anchor="middle" font-size="11" fill="#243b53">R-CHOP/R-EPOCH ‚Üí allo-HSCT if eligible</text>
<text x="160" y="496" text-anchor="middle" font-size="11" fill="#243b53">Clinical trials, checkpoint inhibitors</text>
<text x="160" y="518" text-anchor="middle" font-size="10" fill="#b23a48" font-weight="600">Associated: TP53, NOTCH1, CDKN2A/B, MYC</text>
<!-- NO right -->
<line x1="470" y1="311" x2="640" y2="311" stroke="#2a9d8f" stroke-width="2"/>
<line x1="640" y1="311" x2="640" y2="400" stroke="#2a9d8f" stroke-width="2" marker-end="url(#a3s)"/>
<rect x="570" y="300" width="56" height="16" rx="8" fill="#2a9d8f"/><text x="598" y="312" text-anchor="middle" font-size="9" font-weight="700" fill="#fff">NO (~20%)</text>
<rect x="410" y="404" width="300" height="140" rx="14" fill="#e8f7f5" stroke="#2a9d8f" stroke-width="2.5" filter="url(#ds3)"/>
<text x="560" y="430" text-anchor="middle" font-size="14" font-weight="700" fill="#2a9d8f">Clonally Unrelated DLBCL</text>
<line x1="440" y1="440" x2="680" y2="440" stroke="#2a9d8f" stroke-width=".5"/>
<text x="560" y="460" text-anchor="middle" font-size="11" fill="#243b53">Prognosis like de novo DLBCL</text>
<text x="560" y="478" text-anchor="middle" font-size="11" fill="#243b53">Standard R-CHOP (¬± HSCT)</text>
<text x="560" y="496" text-anchor="middle" font-size="11" fill="#243b53">Much better outcomes</text>
<text x="560" y="518" text-anchor="middle" font-size="10" fill="#2a9d8f" font-weight="600">Treat as independent DLBCL</text>
</svg>
</div>
</div>
<!-- END ALGORITHM 3 -->

<div class="callout red-flag"><div class="callout-label">Red Flag</div><div class="callout-text">Rapid node growth + rising LDH + B symptoms &rarr; suspect Richter transformation. Urgent tissue biopsy from the most metabolically active site (PET-guided) is essential.</div></div>

<div class="clinical-action">
<div class="clinical-action-text"><strong>Supportive Care Checklist &mdash; All CLL Patients:</strong></div>
</div>
<ul class="dx-checklist">
<li><input type="checkbox">Immunoglobulin levels checked regularly; IgG replacement if recurrent infections + low IgG</li>
<li><input type="checkbox">Vaccination: inactivated influenza, pneumococcal, herpes zoster (Shingrix)</li>
<li><input type="checkbox">Hepatitis B screen before ANY anti-CD20 therapy</li>
<li><input type="checkbox">Aciclovir prophylaxis during purine analogue / venetoclax therapy</li>
<li><input type="checkbox">Annual skin surveillance (Merkel cell carcinoma, melanoma risk)</li>
<li><input type="checkbox">DAT monitoring for autoimmune cytopenias</li>
</ul>

<details class="test-yourself">
<summary>Test Yourself &mdash; Module 6</summary>
<div class="mini-q">
<div class="mini-q-stem">A CLL patient has sudden Hb drop to 68 g/L with reticulocytes 10%, LDH 800, haptoglobin undetectable, DAT positive. Platelets also 45 &times; 10<sup>9</sup>/L with preserved megakaryocytes. Diagnosis?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Evans Syndrome</strong> (concurrent AIHA + ITP). Warm AIHA (DAT positive with haemolytic profile) PLUS immune thrombocytopenia (low platelets, preserved megakaryocytes). First-line: corticosteroids. Escalate to rituximab, then anti-CLL therapy if refractory.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">Richter transformation biopsy shows clonally related DLBCL. What is the approximate median overall survival?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>&lt;1 year.</strong> Clonally related (80% of cases) has very poor prognosis. R-CHOP/R-EPOCH &rarr; allo-HSCT if eligible. Clonally unrelated (20%) has much better outcomes, treated like de novo DLBCL.</details>
</div>
</details>
</section>

<!-- MODULE 7: OTHER CHRONIC B-CELL DISORDERS (DETAILED) -->
<section class="module" id="mod-other">
<div class="module-head"><h3>Module 7: Other Chronic B-cell Disorders</h3><span class="module-tag tag-diff">Differential</span></div>
<p class="section-sub">Comprehensive guide to CLL mimics and other chronic B-cell lymphoproliferative disorders with leukaemic expression. Each disorder has actionable diagnostic checklists, treatment pathways, and key differentiators.</p>

<!-- SMZL -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>SMZL &mdash; Splenic Marginal Zone Lymphoma</h4>
<span class="disorder-badge" style="background:rgba(0,109,119,.1);color:var(--teal)">Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Clinical Features</h5>
<ul>
<li>Median age ~70 years; slight M:F predominance</li>
<li><strong>Massive splenomegaly</strong> &mdash; often &gt;6 cm below costal margin</li>
<li>Villous lymphocytes on blood film (short polar villi)</li>
<li>Moderate lymphocytosis (often 10&ndash;30 &times; 10<sup>9</sup>/L)</li>
<li>Autoimmune cytopenias in ~15%</li>
<li>Hepatitis C association (screen all patients)</li>
<li>Minimal or no peripheral lymphadenopathy</li>
</ul>
</div>
<div class="disorder-section">
<h5>Immunophenotype &amp; Genetics</h5>
<ul>
<li>CD19+, CD20+, CD11c+</li>
<li>CD5&minus;, CD23&minus;, CD103&minus;, CD123&minus;, CD25&minus;</li>
<li>No BRAF V600E</li>
<li><strong>NOTCH2 mutations</strong> (10&ndash;25%)</li>
<li>KLF2 mutations (~20%)</li>
<li>del(7q22-32) in ~30% &mdash; most frequent cytogenetic abnormality</li>
<li>BM: <strong>intrasinusoidal infiltration pattern</strong> (characteristic)</li>
</ul>
</div>
</div>
<div class="clinical-action">
<div class="clinical-action-text"><strong>Treatment Pathway:</strong> HCV+ &rarr; treat hepatitis first (may resolve lymphoma). HCV&minus; &rarr; Rituximab monotherapy is standard first-line. Splenectomy reserved for refractory cytopenias or diagnostic uncertainty. OS 10&ndash;15+ years.</div>
</div>
<ul class="dx-checklist" style="margin-top:14px">
<li><input type="checkbox"><strong>Villous lymphocytes</strong> on film</li>
<li><input type="checkbox"><strong>Splenomegaly</strong> confirmed</li>
<li><input type="checkbox">CD103&minus;, CD25&minus;, BRAF&minus; (excludes HCL)</li>
<li><input type="checkbox">Intrasinusoidal BM pattern</li>
<li><input type="checkbox">Hepatitis C screen done</li>
</ul>
</div>
</div>

<!-- HCL -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>HCL &mdash; Hairy-Cell Leukaemia</h4>
<span class="disorder-badge" style="background:rgba(178,58,72,.08);color:var(--cranberry)">Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Clinical Presentation</h5>
<ul>
<li>2% of all leukaemias; <strong>M:F ratio 4:1</strong></li>
<li>Median age 55 years</li>
<li><strong>Pancytopenia with monocytopenia</strong> (hallmark)</li>
<li>Moderate splenomegaly; minimal lymphadenopathy</li>
<li>Hairy cells: pale-grey abundant cytoplasm with fine projections</li>
<li>BM aspirate: <strong>dry tap</strong> (fibrosis)</li>
<li>BM trephine: clear-zone &ldquo;fried-egg&rdquo; infiltration pattern</li>
</ul>
</div>
<div class="disorder-section">
<h5>Immunophenotype &amp; Genetics</h5>
<ul>
<li>CD19+, CD20 bright, CD11c+</li>
<li><strong>CD103+, CD123+, CD25+, Annexin A1+</strong></li>
<li>CD5&minus;, CD23&minus;</li>
<li><strong>BRAF V600E</strong> in virtually 100% (pathognomonic)</li>
<li>IGHV mutated in most cases (usually VH4-34&minus;)</li>
<li>TRAP (tartrate-resistant acid phosphatase) positive</li>
</ul>
</div>
</div>
<div class="disorder-grid" style="margin-top:14px">
<div class="disorder-section" style="background:#e8f7f5;border:1px solid var(--sage)">
<h5 style="color:var(--sage)">First-Line Treatment</h5>
<ul>
<li><strong>Cladribine</strong> (2-CdA) single course &mdash; CR 70&ndash;90%, ORR &gt;95%</li>
<li><strong>Pentostatin</strong> alternative &mdash; similar efficacy</li>
<li>Median remission duration: <strong>15 years</strong></li>
<li>Pre-treatment: G-CSF if neutropenia, aciclovir prophylaxis</li>
</ul>
</div>
<div class="disorder-section" style="background:#fce8ea;border:1px solid var(--cranberry)">
<h5 style="color:var(--cranberry)">Relapsed Disease</h5>
<ul>
<li><strong>Vemurafenib + Rituximab</strong> &mdash; CR &gt;85%, MRD negativity</li>
<li>Repeat purine analogue if remission &gt;5 years</li>
<li>Moxetumomab pasudotox (anti-CD22 immunotoxin)</li>
<li>Ibrutinib shows activity (off-label)</li>
</ul>
</div>
</div>
<div class="clinical-action">
<div class="clinical-action-text"><strong>Diagnostic Pearl:</strong> If pancytopenia + monocytopenia + dry tap + BRAF V600E = Classical HCL until proven otherwise. Annexin A1 is the most specific marker (absent in all mimics).</div>
</div>
<ul class="dx-checklist" style="margin-top:14px">
<li><input type="checkbox"><strong>Pancytopenia</strong> with monocytopenia</li>
<li><input type="checkbox">Hairy cell morphology on film</li>
<li><input type="checkbox">CD103+, CD123+, CD25+, Annexin A1+</li>
<li><input type="checkbox"><strong>BRAF V600E</strong> confirmed</li>
<li><input type="checkbox">BM trephine: clear-zone pattern</li>
<li><input type="checkbox">Pre-treatment infection prophylaxis planned</li>
</ul>
</div>
</div>

<!-- SBCL-PN (HCL Variant) -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>SBCL-PN &mdash; Splenic B-cell Lymphoma/Leukaemia with Prominent Nucleoli</h4>
<span class="disorder-badge" style="background:rgba(224,159,62,.1);color:#b87a20">HCL Variant &middot; Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Key Differences from Classical HCL</h5>
<ul>
<li>WHO 5th edition reclassified from &ldquo;HCL variant&rdquo;</li>
<li><strong>NO BRAF V600E</strong> (critical distinction)</li>
<li>NO monocytopenia (unlike classical HCL)</li>
<li>Usually <strong>leucocytosis</strong> (not pancytopenia)</li>
<li>Cells with prominent nucleoli + hairy projections</li>
<li>Normal MCV (HCL often has raised MCV)</li>
</ul>
</div>
<div class="disorder-section">
<h5>Immunophenotype &amp; Genetics</h5>
<ul>
<li>CD11c+, CD103 &plusmn;, CD123+</li>
<li><strong>CD25&minus;, Annexin A1&minus;</strong></li>
<li><strong>MAP2K1 mutations</strong> common (~40%)</li>
<li>IGHV unmutated in many cases</li>
<li>Often VH4-34 usage (unlike classical HCL)</li>
</ul>
</div>
</div>
<div class="clinical-action">
<div class="clinical-action-text"><strong>Treatment:</strong> Responds poorly to purine analogues alone. <strong>Cladribine + Rituximab</strong> combination achieves better responses. Trametinib (MEK inhibitor) for MAP2K1-mutated cases. Splenectomy in selected refractory patients.</div>
</div>
<div class="callout pitfall" style="margin-top:14px"><div class="callout-label">Pitfall</div><div class="callout-text">Do NOT assume &ldquo;hairy cells = HCL.&rdquo; If CD25&minus; and BRAF&minus;, this is SBCL-PN and requires different treatment. Purine analogues alone are insufficient.</div></div>
</div>
</div>

<!-- Non-nodal MCL -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>Non-nodal Leukaemic Mantle Cell Lymphoma</h4>
<span class="disorder-badge" style="background:rgba(42,157,143,.1);color:var(--sage)">Indolent Subtype &middot; Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Clinical Features</h5>
<ul>
<li>Leukaemic presentation <strong>without significant lymphadenopathy</strong></li>
<li>Splenomegaly may be present</li>
<li>Can <strong>mimic CLL</strong> morphologically</li>
<li>Typically more <strong>indolent course</strong> than nodal MCL</li>
<li>Median age ~65 years</li>
<li>Some patients can be observed (watch &amp; wait)</li>
</ul>
</div>
<div class="disorder-section">
<h5>Immunophenotype &amp; Genetics</h5>
<ul>
<li><strong>Cyclin D1+, t(11;14)(q13;q32)</strong> &mdash; mandatory for diagnosis</li>
<li><strong>SOX11&minus;</strong> (vs SOX11+ in classical nodal MCL)</li>
<li>CD5+, CD200&minus;, CD23&minus;</li>
<li>IGHV mutated in many cases</li>
<li>No TP53 disruption (if present &rarr; aggressive behaviour)</li>
</ul>
</div>
</div>
<div class="clinical-action">
<div class="clinical-action-text"><strong>Management:</strong> If SOX11&minus;, mutated IGHV, no TP53 &rarr; can watch &amp; wait. If treatment needed: BTKi or bendamustine-rituximab. Transform to blastoid/pleomorphic MCL requires aggressive therapy.</div>
</div>
<table class="compare-table" style="margin-top:14px">
<thead><tr><th>Feature</th><th>Non-nodal MCL</th><th>Classical Nodal MCL</th></tr></thead>
<tbody>
<tr><td>SOX11</td><td>Negative</td><td>Positive</td></tr>
<tr><td>Lymphadenopathy</td><td>Absent/minimal</td><td>Present, often bulky</td></tr>
<tr><td>IGHV</td><td>Often mutated</td><td>Usually unmutated</td></tr>
<tr><td>Biology</td><td>Indolent</td><td>Aggressive</td></tr>
<tr><td>Watch &amp; wait?</td><td>Yes (selected)</td><td>Rarely</td></tr>
</tbody>
</table>
</div>
</div>

<!-- FL Leukaemic Phase -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>Follicular Lymphoma &mdash; Leukaemic Phase</h4>
<span class="disorder-badge" style="background:rgba(224,159,62,.1);color:#b87a20">Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Clinical Features</h5>
<ul>
<li>~15% of FL patients have circulating cells</li>
<li><strong>Cleaved nuclei</strong> (centrocytes) with angular cleft &mdash; characteristic on film</li>
<li>Generalised lymphadenopathy is typical</li>
<li>BM: <strong>paratrabecular infiltration</strong> (unlike CLL which is interstitial/diffuse)</li>
</ul>
</div>
<div class="disorder-section">
<h5>Immunophenotype &amp; Genetics</h5>
<ul>
<li><strong>CD10+, BCL6+, BCL2+</strong></li>
<li>CD5&minus;, CD23&minus; or weak</li>
<li><strong>t(14;18)(q32;q21)</strong> &mdash; BCL2 rearrangement</li>
<li>Surface Ig bright (unlike CLL)</li>
</ul>
</div>
</div>
<div class="clinical-action">
<div class="clinical-action-text"><strong>Key Discriminator:</strong> CD10 positivity + t(14;18) + paratrabecular marrow pattern = FL, not CLL. Treatment follows standard FL guidelines (rituximab &plusmn; chemotherapy, obinutuzumab-based regimens).</div>
</div>
</div>
</div>

<!-- LPL/WM -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>LPL / Waldenstr&ouml;m Macroglobulinaemia</h4>
<span class="disorder-badge" style="background:rgba(0,109,119,.1);color:var(--teal)">Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Clinical Features</h5>
<ul>
<li>Small lymphocytes + plasmacytoid cells + plasma cells</li>
<li><strong>Monoclonal IgM paraprotein</strong> (hallmark of WM)</li>
<li>Hyperviscosity symptoms in ~15% (blurred vision, headache, bleeding)</li>
<li>Cold agglutinin disease, cryoglobulinaemia, peripheral neuropathy</li>
<li>Hepatosplenomegaly; lymphadenopathy less prominent</li>
</ul>
</div>
<div class="disorder-section">
<h5>Immunophenotype &amp; Genetics</h5>
<ul>
<li>CD19+, CD20+, CD138+ (plasma cell component)</li>
<li>CD5&minus; or weak, CD10&minus;, CD23&minus;</li>
<li><strong>MYD88 L265P</strong> in &gt;90% (near-pathognomonic)</li>
<li><strong>CXCR4 mutations</strong> in ~30% (affects treatment response)</li>
</ul>
</div>
</div>
<div class="clinical-action">
<div class="clinical-action-text"><strong>Treatment:</strong> Hyperviscosity &rarr; urgent plasmapheresis. First-line: BTKi (zanubrutinib preferred) or BR (bendamustine-rituximab). CXCR4-mutated cases respond less well to BTKi. Avoid rituximab monotherapy upfront if IgM &gt;40 g/L (IgM flare risk).</div>
</div>
<ul class="dx-checklist" style="margin-top:14px">
<li><input type="checkbox">Monoclonal <strong>IgM</strong> paraprotein detected</li>
<li><input type="checkbox">Lymphoplasmacytic morphology on film/BM</li>
<li><input type="checkbox"><strong>MYD88 L265P</strong> tested/confirmed</li>
<li><input type="checkbox">CXCR4 mutation status checked</li>
<li><input type="checkbox">Viscosity level measured (if symptoms)</li>
</ul>
</div>
</div>

<!-- SDRPL -->
<div class="disorder-card">
<div class="disorder-header" onclick="this.parentElement.querySelector('.disorder-body').style.display=this.parentElement.querySelector('.disorder-body').style.display==='none'?'block':'none'">
<h4>SDRPL &mdash; Splenic Diffuse Red Pulp Small B-cell Lymphoma</h4>
<span class="disorder-badge" style="background:rgba(42,157,143,.1);color:var(--sage)">Rare &middot; Click to expand</span>
</div>
<div class="disorder-body">
<div class="disorder-grid">
<div class="disorder-section">
<h5>Key Features</h5>
<ul>
<li>Rare; involves splenic <strong>red pulp diffusely</strong> (not marginal zone)</li>
<li>Villous lymphocytes with round nuclei (unlike SMZL polar villi)</li>
<li>Moderate splenomegaly</li>
<li>CD5&minus;, CD23&minus;, Annexin A1&minus;</li>
<li>CD11c+, CD103+, CD123+, CD25&minus;</li>
</ul>
</div>
<div class="disorder-section">
<h5>Genetics &amp; Prognosis</h5>
<ul>
<li><strong>CCND3 mutations</strong> (Cyclin D3) &mdash; characteristic</li>
<li><strong>Cyclin D3+</strong> by immunohistochemistry</li>
<li>No BRAF V600E (excludes HCL)</li>
<li>Indolent course; splenectomy may be diagnostic and therapeutic</li>
<li>Limited data: rituximab-based therapy if progressive</li>
</ul>
</div>
</div>
</div>
</div>

<!-- MASTER COMPARISON TABLE -->
<div class="card deep" style="margin-top:18px">
<h4>Master Differential Comparison Table</h4>
<div class="table-wrap">
<table class="compare-table">
<thead><tr><th>Feature</th><th>CLL</th><th>SMZL</th><th>HCL</th><th>SBCL-PN</th><th>MCL (nn)</th><th>FL</th><th>LPL/WM</th></tr></thead>
<tbody>
<tr><td><strong>CD5</strong></td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+</td><td>&minus;</td><td>&minus;/w</td></tr>
<tr><td><strong>CD23</strong></td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;/w</td><td>&minus;</td></tr>
<tr><td><strong>CD103</strong></td><td>&minus;</td><td>&minus;</td><td>+</td><td>&plusmn;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>BRAF V600E</strong></td><td>&minus;</td><td>&minus;</td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>Cyclin D1</strong></td><td>&minus;</td><td>&minus;</td><td>w</td><td>&minus;</td><td>+</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>Key mutation</strong></td><td>varies</td><td>NOTCH2</td><td>BRAF</td><td>MAP2K1</td><td>t(11;14)</td><td>t(14;18)</td><td>MYD88</td></tr>
<tr><td><strong>BM pattern</strong></td><td>interstitial</td><td>intrasinusoidal</td><td>clear-zone</td><td>variable</td><td>nodular</td><td>paratrabecular</td><td>mixed</td></tr>
<tr><td><strong>Monocytopenia</strong></td><td>&minus;</td><td>&minus;</td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
</tbody>
</table>
</div>
</div>

<details class="test-yourself" style="margin-top:18px">
<summary>Test Yourself &mdash; Module 7 Quick Check</summary>
<div class="mini-q">
<div class="mini-q-stem">A patient has pancytopenia, monocytopenia, dry tap, and cells that are CD103+, CD25+, Annexin A1+. What single molecular test clinches the diagnosis?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>BRAF V600E mutation.</strong> Present in virtually 100% of classical HCL. Negative in all mimics (SBCL-PN, SMZL, SDRPL).</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">Which disorder has intrasinusoidal BM infiltration, NOTCH2 mutations, and an association with hepatitis C?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>SMZL (Splenic Marginal Zone Lymphoma).</strong> Always screen for HCV &mdash; treating hepatitis may resolve the lymphoma.</details>
</div>
<div class="mini-q">
<div class="mini-q-stem">A patient with t(11;14), Cyclin D1+, SOX11&minus;, and no lymphadenopathy. Diagnosis and management approach?</div>
<details class="mini-q-reveal"><summary>Reveal Answer</summary><strong>Non-nodal leukaemic MCL.</strong> SOX11&minus; with no nodes = indolent subtype. Can be observed if no TP53 disruption and mutated IGHV.</details>
</div>
</details>
</section>


<!-- QUIZ ZONE -->
<section class="quiz-zone" id="quiz-zone">
<div style="display:flex;justify-content:space-between;align-items:center;flex-wrap:wrap;gap:12px;margin-bottom:14px">
<h3 style="font-size:1.5rem">Quiz Zone</h3>
<div style="font-size:.82rem;color:var(--teal);font-weight:600">Bloodü©∏Doctor By Dr Abdul Mannan FRCPath FCPS</div>
</div>
<div class="quiz-tabs">
<button class="quiz-tab active" id="tabMCQ" onclick="switchTab('mcq')">MCQ (20)</button>
<button class="quiz-tab" id="tabEMQ" onclick="switchTab('emq')">EMQ (20)</button>
<button class="quiz-tab" id="tabVMCQ" onclick="switchTab('vmcq')">Vignette MCQ (15)</button>
<button class="quiz-tab" id="tabVEMQ" onclick="switchTab('vemq')">Vignette EMQ (10)</button>
</div>
<div class="quiz-progress"><div class="quiz-progress-bar" id="progressBar" style="width:0%"></div></div>
<div id="quizContainer"></div>
<div class="results-card" id="resultsCard">
<div class="results-score" id="resScore">0%</div>
<div class="results-award" id="resAward"></div>
<div class="results-grid">
<div class="results-stat"><div class="label">MCQ</div><div class="value" id="resMCQ">0%</div></div>
<div class="results-stat"><div class="label">EMQ</div><div class="value" id="resEMQ">0%</div></div>
<div class="results-stat"><div class="label">Vignette MCQ</div><div class="value" id="resVMCQ">0%</div></div>
<div class="results-stat"><div class="label">Vignette EMQ</div><div class="value" id="resVEMQ">0%</div></div>
<div class="results-stat"><div class="label">Overall</div><div class="value" id="resOverall">0%</div></div>
</div>
<div id="resGuidance" style="text-align:left;padding:14px;border-radius:12px;background:var(--bg-ivory);margin-top:14px;display:none"></div>
<div style="margin-top:18px;display:flex;gap:12px;justify-content:center">
<button class="cta-primary" onclick="resetQuiz()">Reset & Reshuffle</button>
<button class="cta-outline" onclick="showAllQuestions()">Review Answers</button>
</div>
</div>
<div style="margin-top:14px;display:flex;gap:12px;flex-wrap:wrap">
<button class="cta-primary" id="finishBtn" onclick="finishQuiz()" style="display:none">Finish & Score</button>
<button class="cta-outline" onclick="resetQuiz()">Reset</button>
</div>
</section>

<!-- BIBLIOGRAPHY -->
<section class="module" id="mod-bib">
<div class="module-head"><h3>Bibliography & Abbreviations</h3><span class="module-tag tag-dx">Reference</span></div>
<div class="card">
<h4>Core References</h4>
<ol style="font-size:.85rem;line-height:1.8;padding-left:18px">
<li>Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <em>Blood.</em> 2018;131:2745-2760.</li>
<li>Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guideline. <em>Ann Oncol.</em> 2021;32:23-33.</li>
<li>Eichhorst B, et al. ESMO update for CLL (2024). <em>Ann Oncol.</em> 2024.</li>
<li>Grever MR, Abdel-Wahab O, et al. Consensus guidelines for classic hairy cell leukemia. <em>Blood.</em> 2017;129:553-560.</li>
<li>Montserrat E. Chapter 23: CLL and other chronic B-cell lymphoproliferative disorders. In: <em>Hoffbrand's Postgraduate Haematology</em>, 8th ed. Wiley; 2025.</li>
</ol>
</div>
<details>
<summary>Abbreviations</summary>
<div class="table-wrap">
<table>
<tbody>
<tr><td><strong>AIHA</strong></td><td>Autoimmune haemolytic anaemia</td></tr>
<tr><td><strong>BCL2i</strong></td><td>BCL2 inhibitor (e.g., venetoclax)</td></tr>
<tr><td><strong>BCR</strong></td><td>B-cell receptor</td></tr>
<tr><td><strong>BTKi</strong></td><td>Bruton tyrosine kinase inhibitor</td></tr>
<tr><td><strong>CIT</strong></td><td>Chemoimmunotherapy</td></tr>
<tr><td><strong>CLL</strong></td><td>Chronic lymphocytic leukaemia</td></tr>
<tr><td><strong>DAT</strong></td><td>Direct antiglobulin test</td></tr>
<tr><td><strong>DLBCL</strong></td><td>Diffuse large B-cell lymphoma</td></tr>
<tr><td><strong>FCR</strong></td><td>Fludarabine, cyclophosphamide, rituximab</td></tr>
<tr><td><strong>FISH</strong></td><td>Fluorescence in situ hybridisation</td></tr>
<tr><td><strong>HCL</strong></td><td>Hairy-cell leukaemia</td></tr>
<tr><td><strong>IGHV</strong></td><td>Immunoglobulin heavy-chain variable region</td></tr>
<tr><td><strong>ITP</strong></td><td>Immune thrombocytopenia</td></tr>
<tr><td><strong>LDT</strong></td><td>Lymphocyte doubling time</td></tr>
<tr><td><strong>MBL</strong></td><td>Monoclonal B-cell lymphocytosis</td></tr>
<tr><td><strong>MCL</strong></td><td>Mantle cell lymphoma</td></tr>
<tr><td><strong>MRD</strong></td><td>Minimal residual disease</td></tr>
<tr><td><strong>PRCA</strong></td><td>Pure red-cell aplasia</td></tr>
<tr><td><strong>SLL</strong></td><td>Small lymphocytic lymphoma</td></tr>
<tr><td><strong>SMZL</strong></td><td>Splenic marginal zone lymphoma</td></tr>
<tr><td><strong>TP53</strong></td><td>Tumour protein p53</td></tr>
<tr><td><strong>uMRD</strong></td><td>Undetectable minimal residual disease</td></tr>
</tbody>
</table>
</div>
</details>
</section>

</main>

<!-- FOOTER -->
<footer class="footer">
<div><strong>Bloodü©∏Doctor</strong> By Dr Abdul Mannan FRCPath FCPS &middot; blooddoctor.co@gmail.com</div>
<div>Educational resource for trainees. Not a substitute for clinical judgement. Content derived from Hoffbrand's Postgraduate Haematology, 8th edition.</div>
</footer>
</div>

<script>
// === QUIZ BANK ===
const QUIZ_BANK={mcq:[{id:"m1",type:"mcq",stem:"A patient has persistent monoclonal B-lymphocytosis of 6 \u00d7 10\u2079/L for 4 months with typical CLL phenotype and no tissue biopsy. Most appropriate diagnosis?",options:["MBL","CLL","SLL","LPL"],correctIndex:1,rationale:"CLL requires \u22655 \u00d7 10\u2079/L clonal B cells in blood for \u22653 months with compatible phenotype.",topic:"Diagnosis",difficulty:"easy"},{id:"m2",type:"mcq",stem:"Which immunophenotype is most consistent with typical CLL?",options:["CD5\u2212, CD23\u2212, strong SmIg","CD5+, CD23+, CD200+, weak SmIg/CD20","CD10+, BCL6+, CD5\u2212","CD103+, CD123+, Annexin A1+"],correctIndex:1,rationale:"Typical CLL co-expresses CD5 and CD23 with weak surface immunoglobulin and CD20, often CD200+.",topic:"Immunophenotype",difficulty:"easy"},{id:"m3",type:"mcq",stem:"Which genetic profile most strongly predicts poor response to chemoimmunotherapy?",options:["Isolated del(13q)","Trisomy 12 alone","del(17p)/TP53 disruption","Mutated IGHV only"],correctIndex:2,rationale:"TP53 pathway disruption is the key marker of poor CIT response and guides pathway inhibitor use.",topic:"Predictive biomarkers",difficulty:"medium"},{id:"m4",type:"mcq",stem:"In CLL, unmutated IGHV status generally indicates:",options:["More indolent biology","Better CIT outcomes","More aggressive clinical behaviour","No prognostic relevance"],correctIndex:2,rationale:"IGHV-unmutated disease tends toward faster progression and historically inferior CIT outcomes.",topic:"Prognosis",difficulty:"easy"},{id:"m5",type:"mcq",stem:"Which feature alone is NOT a treatment-start criterion in otherwise stable CLL?",options:["Hb <110 g/L from marrow failure","Progressive symptomatic splenomegaly","High WBC count without other active-disease features","B symptoms"],correctIndex:2,rationale:"High leukocyte count by itself usually does not justify treatment initiation.",topic:"Treatment criteria",difficulty:"easy"},{id:"m6",type:"mcq",stem:"A CLL patient on BTKi develops transient rising lymphocyte count but improving nodes and symptoms. Best interpretation?",options:["Definite progression","Expected redistribution effect","Richter transformation","Autoimmune flare"],correctIndex:1,rationale:"BTKi can cause temporary blood lymphocytosis due to tissue redistribution.",topic:"Treatment monitoring",difficulty:"medium"},{id:"m7",type:"mcq",stem:"In suspected Richter transformation, the most urgent next step is:",options:["Increase steroid dose only","Start empiric chlorambucil","Tissue biopsy from metabolically active site","Repeat CBC in 3 months"],correctIndex:2,rationale:"Transformation requires histologic confirmation; PET/CT helps identify the best biopsy site.",topic:"Complications",difficulty:"medium"},{id:"m8",type:"mcq",stem:"AIHA in CLL is most likely when anaemia is accompanied by:",options:["Low LDH and high haptoglobin","Elevated LDH and positive DAT","Normal smear and DAT negative","Isolated neutropenia only"],correctIndex:1,rationale:"A haemolytic profile with DAT positivity strongly supports AIHA.",topic:"Autoimmune cytopenias",difficulty:"easy"},{id:"m9",type:"mcq",stem:"Which first-line approach is standard for most asymptomatic early CLL?",options:["Immediate CIT","Immediate BTKi for all","Active surveillance","Splenectomy"],correctIndex:2,rationale:"Early asymptomatic disease is managed with watchful waiting.",topic:"Treatment strategy",difficulty:"easy"},{id:"m10",type:"mcq",stem:"A major toxicity profile classically associated with ibrutinib includes:",options:["Severe neuropathy only","Atrial fibrillation, hypertension, bleeding","Hyperpigmentation only","Isolated nephrotoxicity only"],correctIndex:1,rationale:"Cardiovascular and bleeding toxicities are key class effects.",topic:"Targeted therapy",difficulty:"easy"},{id:"m11",type:"mcq",stem:"Why is venetoclax dose ramp-up required?",options:["To prevent cytokine storm","To prevent tumour lysis syndrome","To reduce neuropathy","To improve oral absorption only"],correctIndex:1,rationale:"Gradual escalation reduces tumour lysis risk.",topic:"Targeted therapy",difficulty:"easy"},{id:"m12",type:"mcq",stem:"Which statement best fits isolated del(13q) in CLL?",options:["Universally refractory disease","Generally favourable prognostic pattern","Indicates Hodgkin transformation","Contraindicates all targeted agents"],correctIndex:1,rationale:"Isolated del(13q) is usually linked with more favourable biology.",topic:"Prognosis",difficulty:"easy"},{id:"m13",type:"mcq",stem:"Which marker combination most supports classical HCL?",options:["CD5+, CD23+, Cyclin D1+","CD11c+, CD25+, CD103+, CD123+, BRAF V600E","CD10+, BCL6+, t(14;18)","CD5+, CD23\u2212, SOX11+"],correctIndex:1,rationale:"Classical HCL has a characteristic marker profile and near-universal BRAF V600E.",topic:"HCL",difficulty:"medium"},{id:"m14",type:"mcq",stem:"Standard front-line therapy for most active classical HCL cases is:",options:["Chlorambucil monotherapy","Purine analogue (cladribine or pentostatin)","Splenectomy first in all","Immediate allo-HSCT"],correctIndex:1,rationale:"Purine analogues provide high and durable responses.",topic:"HCL treatment",difficulty:"easy"},{id:"m15",type:"mcq",stem:"Which feature favours splenic B-cell lymphoma/leukaemia with prominent nucleoli over classical HCL?",options:["Universal BRAF V600E","CD25 negativity and no BRAF V600E","Frequent monocytopenia","Dry tap in almost all cases"],correctIndex:1,rationale:"The variant form typically lacks CD25 and BRAF V600E.",topic:"HCL variant",difficulty:"medium"},{id:"m16",type:"mcq",stem:"In SMZL, which pattern is most characteristic?",options:["CD103 and CD123 co-expression in all cases","Intrasinusoidal marrow infiltration with villous lymphocytes","Cyclin D1 overexpression from t(11;14)","No splenic involvement"],correctIndex:1,rationale:"SMZL often shows villous lymphocytes and intrasinusoidal marrow involvement.",topic:"SMZL",difficulty:"medium"},{id:"m17",type:"mcq",stem:"Which finding helps distinguish non-nodal leukaemic MCL from typical CLL?",options:["Consistent CD23 bright positivity","Cyclin D1 expression and t(11;14)","Frequent smudge cells only","Universal CD200 positivity"],correctIndex:1,rationale:"Cyclin D1 and t(11;14) are central discriminatory markers for MCL.",topic:"MCL differential",difficulty:"medium"},{id:"m18",type:"mcq",stem:"Which statement about MBL is most accurate?",options:["Always requires immediate therapy","Defined by \u22655 \u00d7 10\u2079/L clonal B cells","Usually monitored; progression risk exists but is limited","Equivalent to aggressive lymphoma"],correctIndex:2,rationale:"MBL is a precursor state; monitoring is standard unless progression occurs.",topic:"MBL",difficulty:"easy"},{id:"m19",type:"mcq",stem:"A CLL patient with refractory autoimmune cytopenia despite standard immune therapy should next be considered for:",options:["Observation only","Anti-CLL directed therapy","Antibiotics alone","Immediate splenectomy in all cases"],correctIndex:1,rationale:"Refractory autoimmune cytopenia is an accepted trigger for anti-CLL therapy.",topic:"Autoimmune cytopenias",difficulty:"medium"},{id:"m20",type:"mcq",stem:"Which is true about response categories in CLL trials?",options:["MRD status has no clinical value","CR with undetectable MRD tends to have better outcomes","PR requires normal marrow biopsy","Stable disease means all symptoms resolved"],correctIndex:1,rationale:"uMRD CR generally correlates with deeper response quality and better outcomes.",topic:"Response assessment",difficulty:"medium"}],emq:[{id:"e1",type:"emq",stem:"Clonal B cells 3 \u00d7 10\u2079/L, no adenopathy, no organomegaly, no symptoms.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:2,rationale:"Below 5 \u00d7 10\u2079/L clonal B cells without disease features supports MBL.",topic:"Diagnostic classification",difficulty:"easy"},{id:"e2",type:"emq",stem:"Typical CLL phenotype with clonal B cells 8 \u00d7 10\u2079/L for 4 months.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:0,rationale:"Meets blood count and duration threshold for CLL.",topic:"Diagnostic classification",difficulty:"easy"},{id:"e3",type:"emq",stem:"Tissue-dominant disease with CLL phenotype but blood clonal B cells <5 \u00d7 10\u2079/L.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:1,rationale:"SLL represents tissue-dominant disease within the same biologic spectrum.",topic:"Diagnostic classification",difficulty:"medium"},{id:"e4",type:"emq",stem:"Villous lymphocytes, splenomegaly, intrasinusoidal marrow pattern, CD11c+, CD103\u2212.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:3,rationale:"This profile is classic for SMZL.",topic:"Diagnostic classification",difficulty:"medium"},{id:"e5",type:"emq",stem:"Cyclin D1 positivity with t(11;14) in a leukaemic presentation.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:5,rationale:"t(11;14) with cyclin D1 is strongly supportive of MCL.",topic:"Diagnostic classification",difficulty:"medium"},{id:"e6",type:"emq",stem:"Biomarker most linked with CIT resistance and pathway-inhibitor preference.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:1,rationale:"TP53 disruption drives major resistance to CIT.",topic:"Predictive markers",difficulty:"easy"},{id:"e7",type:"emq",stem:"Pattern more often associated with indolent biology and longer treatment-free interval.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:3,rationale:"Mutated IGHV generally indicates slower disease behaviour.",topic:"Prognosis",difficulty:"easy"},{id:"e8",type:"emq",stem:"Marker associated with aggressive disease kinetics and quicker need for treatment.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:6,rationale:"Short LDT indicates rapid clonal expansion.",topic:"Prognosis",difficulty:"medium"},{id:"e9",type:"emq",stem:"Mutation linked to clinical resistance during BTKi therapy.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:8,rationale:"BTK pathway mutations are a known mechanism of BTKi resistance.",topic:"Relapse biology",difficulty:"hard"},{id:"e10",type:"emq",stem:"Mutation pattern associated with resistance during venetoclax therapy.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:9,rationale:"Acquired BCL2 resistance mutations can drive venetoclax failure.",topic:"Relapse biology",difficulty:"hard"},{id:"e11",type:"emq",stem:"Sudden anaemia, high LDH, low haptoglobin, DAT positive.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:0,rationale:"This haemolytic pattern supports AIHA.",topic:"Complications",difficulty:"easy"},{id:"e12",type:"emq",stem:"CLL with severe isolated thrombocytopenia, marrow megakaryocytes preserved.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:1,rationale:"Pattern is consistent with immune thrombocytopenia.",topic:"Complications",difficulty:"medium"},{id:"e13",type:"emq",stem:"AIHA plus immune thrombocytopenia occurring together.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:7,rationale:"Combined AIHA and ITP defines Evans syndrome.",topic:"Complications",difficulty:"easy"},{id:"e14",type:"emq",stem:"Rapid clinical deterioration, rising LDH, aggressive DLBCL clone with poor prognosis.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:3,rationale:"Clonally related Richter transformation is typically high risk.",topic:"Complications",difficulty:"hard"},{id:"e15",type:"emq",stem:"Rising lymphocyte count soon after BTKi initiation despite improving nodes.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:5,rationale:"This is expected redistribution, not immediate progression.",topic:"Treatment monitoring",difficulty:"medium"},{id:"e16",type:"emq",stem:"Newly diagnosed asymptomatic early CLL without active disease criteria.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:0,rationale:"Observation is standard when no treatment trigger is present.",topic:"Treatment selection",difficulty:"easy"},{id:"e17",type:"emq",stem:"Fit younger patient with favourable biology where CIT is still selectively considered.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:3,rationale:"FCR may remain an option in selected younger fit patients.",topic:"Treatment selection",difficulty:"medium"},{id:"e18",type:"emq",stem:"CLL relapse after one pathway-inhibitor class with renewed treatment indication.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:2,rationale:"Class-switch strategy is core in relapsed disease management.",topic:"Relapsed CLL",difficulty:"hard"},{id:"e19",type:"emq",stem:"Classical HCL with treatment indication and no major contraindication.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:6,rationale:"Purine analogues are standard front-line for active classical HCL.",topic:"HCL treatment",difficulty:"easy"},{id:"e20",type:"emq",stem:"Suspected Richter transformation based on abrupt clinical shift and high LDH.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:9,rationale:"Histologic confirmation by tissue biopsy is essential.",topic:"Complications",difficulty:"medium"}],
vmcq:[
{id:"cv1",type:"mcq",stem:"A 72-year-old man presents with fatigue and recurrent sinopulmonary infections over 6 months. FBC: WBC 68 \u00d7 10\u2079/L (lymphocytes 62 \u00d7 10\u2079/L), Hb 128 g/L, platelets 185 \u00d7 10\u2079/L. Blood film: small mature lymphocytes, smudge cells. Flow cytometry: CD5+, CD19+, CD23+, CD200+, weak SmIg, FMC7\u2212. FISH: isolated del(13q14). IGHV mutated. Serum IgG 3.2 g/L (normal 6\u201316). No palpable lymphadenopathy. What is the most appropriate next management step?",options:["Start ibrutinib","Start FCR","Active surveillance with IgG monitoring","Immediate venetoclax + obinutuzumab"],correctIndex:2,rationale:"This is Rai stage 0 with mutated IGHV and favourable del(13q). Despite hypogammaglobulinaemia, treatment is only for active/progressive disease. IgG replacement may be considered if recurrent infections worsen, but CLL-directed therapy is not yet indicated.",topic:"Treatment criteria",difficulty:"hard"},
{id:"cv2",type:"mcq",stem:"A 58-year-old woman with CLL (unmutated IGHV, no TP53 abnormality) started ibrutinib 6 weeks ago for progressive bulky lymphadenopathy. At follow-up, lymph nodes decreased by 40%, spleen non-palpable, but absolute lymphocyte count has risen from 45 to 112 \u00d7 10\u2079/L. She feels well with no B symptoms. What is the most appropriate interpretation?",options:["Treatment failure requiring immediate switch to venetoclax","Richter transformation","Expected pharmacological redistribution lymphocytosis","Laboratory error requiring repeat testing"],correctIndex:2,rationale:"BTK inhibitors mobilise CLL cells from tissue compartments into blood, causing transient lymphocytosis that can persist for months. This is NOT progression \u2014 clinical response is defined by nodal/splenic reduction, not blood counts.",topic:"Treatment monitoring",difficulty:"hard"},
{id:"cv3",type:"mcq",stem:"A 65-year-old man with CLL (Binet B, unmutated IGHV, 8 years) presents with sudden worsening fatigue, drenching night sweats, 8 kg weight loss in 4 weeks, and rapidly enlarging right cervical node now 7 cm. LDH risen from 210 to 890 U/L. Beta-2 microglobulin 8.4 mg/L. What is the single most important next investigation?",options:["Repeat FISH panel for del(17p)","PET/CT with guided tissue biopsy of the most active node","CT chest/abdomen with 3-month follow-up","Bone marrow aspirate and trephine only"],correctIndex:1,rationale:"The clinical picture strongly suggests Richter transformation: abrupt B symptoms, rapidly enlarging single mass, markedly elevated LDH. PET/CT identifies the most metabolically active site (SUVmax often >5) to guide biopsy for histological confirmation.",topic:"Richter transformation",difficulty:"hard"},
{id:"cv4",type:"mcq",stem:"A 74-year-old woman with CLL (Rai II) develops progressive anaemia. Hb 78 g/L, reticulocytes 8.2%, LDH 620 U/L, haptoglobin undetectable, bilirubin 42 \u03bcmol/L (unconjugated predominant), DAT strongly positive (IgG + C3d). Platelets 155 \u00d7 10\u2079/L. Film shows spherocytes and polychromasia. What is the most likely diagnosis?",options:["Marrow infiltration by CLL","Pure red cell aplasia","Autoimmune haemolytic anaemia","Microangiopathic haemolytic anaemia"],correctIndex:2,rationale:"Reticulocytosis, elevated LDH, absent haptoglobin, unconjugated hyperbilirubinaemia, positive DAT (IgG+C3d), and spherocytes is diagnostic of warm AIHA (~10% of CLL). PRCA shows low reticulocytes. Marrow infiltration causes hypoproliferative anaemia. MAHA shows schistocytes.",topic:"Autoimmune complications",difficulty:"hard"},
{id:"cv5",type:"mcq",stem:"A 62-year-old man diagnosed with CLL: WBC 28 \u00d7 10\u2079/L, Hb 142 g/L, platelets 220 \u00d7 10\u2079/L. CLL score 5/5. FISH: del(17p13.1) in 35% of nuclei. TP53 mutation confirmed by NGS. IGHV unmutated. No lymphadenopathy or organomegaly, asymptomatic. What is the most appropriate management?",options:["Immediate ibrutinib","Immediate venetoclax + obinutuzumab","Active surveillance with close monitoring","FCR given his fitness"],correctIndex:2,rationale:"Despite high-risk biology (del(17p)/TP53, unmutated IGHV), treatment is ONLY initiated when active disease criteria are met. This is Rai 0 with no symptoms, cytopenias, or organomegaly. Close monitoring essential given high-risk genetics, but early treatment has not shown benefit. FCR contraindicated with TP53.",topic:"Treatment criteria",difficulty:"hard"},
{id:"cv6",type:"mcq",stem:"A 55-year-old woman with CLL (mutated IGHV, normal FISH, Binet C with Hb 92 g/L from marrow failure) is being considered for first-line therapy. Fit, ECOG 0, no significant comorbidities, CrCl 95 mL/min. Which treatment option may still be considered in this specific subgroup?",options:["Chlorambucil monotherapy","Bendamustine-rituximab only","FCR (fludarabine, cyclophosphamide, rituximab)","Splenectomy as first-line"],correctIndex:2,rationale:"In fit, young patients with mutated IGHV and no TP53 disruption, FCR remains a legitimate option with potential for long-term remission (60%+ of mutated IGHV patients achieve >10 year remissions). While BTKi/BCL2i are increasingly preferred, FCR is still selectively considered in this favourable subgroup.",topic:"First-line therapy",difficulty:"hard"},
{id:"cv7",type:"mcq",stem:"A 68-year-old man with CLL (unmutated IGHV) on ibrutinib for 3 years with good response now presents with progressive lymphadenopathy and rising LDH despite continued therapy. Marrow confirms CLL (no transformation). Sequencing reveals BTK C481S mutation. What is the most appropriate next step?",options:["Increase ibrutinib dose to 560 mg twice daily","Switch to venetoclax-based therapy","Add rituximab to ibrutinib","Proceed directly to allo-HSCT"],correctIndex:1,rationale:"BTK C481S is the commonest acquired resistance mechanism to covalent BTKi, disrupting the covalent binding site. Standard approach is class-switch to venetoclax \u00b1 anti-CD20. Dose escalation will not overcome the resistance mutation.",topic:"Relapse management",difficulty:"hard"},
{id:"cv8",type:"mcq",stem:"A 70-year-old woman presents with pancytopenia: WBC 2.8 \u00d7 10\u2079/L (monocytes 0.1 \u00d7 10\u2079/L \u2014 markedly reduced), Hb 98 g/L, platelets 72 \u00d7 10\u2079/L. Film: lymphoid cells with pale grey cytoplasm and fine hair-like projections. BM aspirate: dry tap. Flow: CD19+, CD11c+, CD25+, CD103+, CD123+, Annexin A1+, CD5\u2212, CD23\u2212. BRAF V600E confirmed. First-line treatment?",options:["Rituximab monotherapy","Cladribine","Ibrutinib","Splenectomy"],correctIndex:1,rationale:"This is classical HCL (pancytopenia with monocytopenia, hairy cells, dry tap, Annexin A1+, BRAF V600E). First-line: purine analogue (cladribine or pentostatin), achieving durable CR in >80%. Splenectomy is historical.",topic:"HCL treatment",difficulty:"hard"},
{id:"cv9",type:"mcq",stem:"A 75-year-old woman presents with massive splenomegaly (14 cm below costal margin), WBC 18 \u00d7 10\u2079/L with circulating lymphoid cells showing short villous projections. Flow: CD19+, CD11c+, CD5\u2212, CD23\u2212, CD103\u2212, CD25\u2212, BRAF V600E negative. NOTCH2 mutation detected. BM biopsy: intrasinusoidal infiltration. Diagnosis?",options:["Classical HCL","Splenic marginal zone lymphoma","CLL","Follicular lymphoma"],correctIndex:1,rationale:"Villous lymphocytes + massive splenomegaly + intrasinusoidal marrow + CD103\u2212/CD25\u2212/BRAF\u2212 + NOTCH2 mutation is classic SMZL. Classical HCL would have CD103+/CD25+/BRAF+. CLL would be CD5+/CD23+.",topic:"Differential diagnosis",difficulty:"hard"},
{id:"cv10",type:"mcq",stem:"A 60-year-old man with CLL (Binet A, 2 years) has routine bloods: WBC 32 \u00d7 10\u2079/L, Hb 138 g/L, platelets 195 \u00d7 10\u2079/L. WBC was 18 \u00d7 10\u2079/L 12 months ago and 24 \u00d7 10\u2079/L 6 months ago. No symptoms, no palpable lymphadenopathy, no organomegaly. What is the LDT and does this patient need treatment?",options:["LDT ~12 months \u2014 meets treatment criteria","LDT ~12 months \u2014 borderline, continue close monitoring","LDT ~6 months \u2014 meets treatment criteria","LDT ~24 months \u2014 active surveillance"],correctIndex:1,rationale:"LDT is approximately 12 months (18\u219232 over 12 months). iwCLL guidelines specify LDT <6 months as treatment trigger, or >50% rise in 2 months. LDT of 12 months is borderline \u2014 warrants closer monitoring but does not mandate treatment alone.",topic:"Prognosis and monitoring",difficulty:"hard"},
{id:"cv11",type:"mcq",stem:"A 64-year-old man starting venetoclax for relapsed CLL. WBC 120 \u00d7 10\u2079/L with bulky 8 cm abdominal lymphadenopathy. Creatinine 98 \u03bcmol/L, urate 480 \u03bcmol/L, potassium 4.8 mmol/L. What is the most critical safety measure?",options:["Immediate full-dose venetoclax 400 mg daily","5-week dose ramp-up with TLS prophylaxis, hydration, and monitoring","Loading dose of 800 mg for 3 days then maintenance","Start with rituximab alone for 2 cycles first"],correctIndex:1,rationale:"Venetoclax causes rapid apoptosis creating high TLS risk with high tumour burden. Mandatory: 5-week ramp-up (20\u219250\u2192100\u2192200\u2192400 mg), aggressive hydration, allopurinol/rasburicase, serial TLS monitoring at 6-8h and 24h post-dose.",topic:"Venetoclax management",difficulty:"hard"},
{id:"cv12",type:"mcq",stem:"A 52-year-old man presents with lymphocytosis 35 \u00d7 10\u2079/L. Flow: CD5+, CD19+, CD20 bright, CD23\u2212, CD200\u2212, FMC7+, strong SmIg (lambda). CLL score: 1/5. Cytogenetics: t(11;14)(q13;q32). Cyclin D1+. SOX11 negative. No lymphadenopathy, spleen just palpable. Diagnosis?",options:["Typical CLL","Classical HCL","Non-nodal leukaemic mantle cell lymphoma","SMZL"],correctIndex:2,rationale:"Low CLL score (1/5), bright CD20, strong SmIg, CD23\u2212, CD200\u2212, plus t(11;14) and Cyclin D1+ = MCL. SOX11 negativity with leukaemic non-nodal presentation = non-nodal leukaemic MCL \u2014 a more indolent subtype that mimics CLL.",topic:"Differential diagnosis",difficulty:"hard"},
{id:"cv13",type:"mcq",stem:"A 78-year-old woman with CLL (ibrutinib 2 years) develops new palpitations. ECG: irregularly irregular rhythm 128 bpm, absent P waves. BP 108/72 mmHg, haemodynamically stable. Most important consideration?",options:["Ibrutinib has no cardiac effects; investigate other causes","Likely ibrutinib-associated atrial fibrillation; assess bleeding risk and consider rate control","Stop ibrutinib immediately and switch to chlorambucil","Cardiovert immediately under GA"],correctIndex:1,rationale:"AF occurs in 5\u201316% of ibrutinib patients. Management: rate control (beta-blocker preferred; avoid verapamil/diltiazem due to CYP3A4 interaction), cautious anticoagulation (DOACs, avoid warfarin). Consider switching to more selective BTKi (acalabrutinib/zanubrutinib).",topic:"BTKi toxicity",difficulty:"hard"},
{id:"cv14",type:"mcq",stem:"A 66-year-old man with CLL (Binet B) is being considered for obinutuzumab. Before starting treatment, which screening test is most critical to prevent a potentially fatal complication?",options:["HIV serology only","Hepatitis B surface antigen, anti-HBs, and anti-HBc","Tuberculosis IGRA only","CMV PCR only"],correctIndex:1,rationale:"Anti-CD20 antibodies cause profound B-cell depletion and can trigger fulminant HBV reactivation \u2014 even with resolved infection (HBsAg\u2212/anti-HBc+). Full HBV screening mandatory before ANY anti-CD20 therapy. Positive patients need antiviral prophylaxis for \u226512 months after treatment.",topic:"Supportive care",difficulty:"hard"},
{id:"cv15",type:"mcq",stem:"A 45-year-old woman presents with lymphocytosis 4.2 \u00d7 10\u2079/L (clonal B cells 3.8 \u00d7 10\u2079/L). Flow: CD5+, CD19+, CD23+, CLL score 5/5. No lymphadenopathy on CT, no organomegaly, no cytopenias, no symptoms. IGHV mutated, normal FISH. Diagnosis and approximate risk of progression to CLL requiring treatment?",options:["CLL \u2014 immediate treatment needed","Low-count MBL \u2014 ~1% per year progression to CLL needing treatment","High-count MBL \u2014 ~1-2% per year progression","SLL \u2014 tissue biopsy required"],correctIndex:2,rationale:"Clonal B cells <5 \u00d7 10\u2079/L with CLL phenotype and no tissue disease = MBL. This is high-count MBL (0.5\u20135 \u00d7 10\u2079/L) with ~1\u20132% per year progression risk. Regular monitoring (6\u201312 months) recommended, no treatment indicated.",topic:"MBL prognosis",difficulty:"hard"}
],
vemq:[
{id:"ce1",type:"emq",stem:"A 71-year-old man with CLL (unmutated IGHV, del(11q)) on ibrutinib 4 years. Progressive lymphadenopathy despite compliance. Sequencing: BTK C481S and PLC\u03b32 mutations. ECOG 0, no TP53 abnormality. Most appropriate next treatment?",options:["Venetoclax + rituximab (fixed duration)","Continue ibrutinib higher dose","Acalabrutinib (same class switch)","FCR salvage","Idelalisib + rituximab","Chlorambucil + obinutuzumab","Allo-HSCT as immediate next step","CAR-T cell therapy","Radiotherapy to bulky sites","Observation only"],correctIndex:0,rationale:"After covalent BTKi failure with C481S/PLC\u03b32 mutations, class-switch to venetoclax is standard. Another covalent BTKi would fail due to shared resistance mechanism.",topic:"Relapse management",difficulty:"hard"},
{id:"ce2",type:"emq",stem:"A 69-year-old woman with CLL (mutated IGHV, isolated del(13q), Binet C, Hb 94 g/L from marrow failure). Well-controlled hypertension, ECOG 1, CrCl 78 mL/min. Most appropriate first-line treatment?",options:["Venetoclax + obinutuzumab (fixed duration)","Ibrutinib continuous","Acalabrutinib + obinutuzumab","FCR","Bendamustine + rituximab","Chlorambucil + obinutuzumab","Allo-HSCT","CAR-T cell therapy","Radiotherapy","Observation only"],correctIndex:0,rationale:"For older fit patients with mutated IGHV requiring first-line treatment, venetoclax + obinutuzumab offers fixed-duration (12 months) with deep responses and uMRD >75%. Avoids continuous BTKi cardiovascular toxicity.",topic:"First-line treatment",difficulty:"hard"},
{id:"ce3",type:"emq",stem:"A 73-year-old man with CLL develops severe AIHA: Hb 62 g/L, reticulocytes 12%, DAT positive. Prednisolone 1 mg/kg for 3 weeks, Hb only 72 g/L with ongoing haemolysis. Next best step?",options:["Rituximab","Ibrutinib for CLL","Splenectomy","Cyclosporine","Mycophenolate mofetil","Danazol","Red cell exchange","IV immunoglobulin","Plasma exchange","Continue steroids"],correctIndex:0,rationale:"Steroid-refractory warm AIHA in CLL: standard escalation is rituximab (375 mg/m\u00b2 weekly \u00d7 4), achieving 70\u201380% responses. If refractory, CLL-directed therapy (BTKi/venetoclax) is then considered.",topic:"AIHA management",difficulty:"hard"},
{id:"ce4",type:"emq",stem:"A 55-year-old man with classical HCL (BRAF V600E+). Achieved CR with cladribine 2 years ago. Now relapses with same features (pancytopenia, hairy cells, dry tap). Most appropriate treatment?",options:["Repeat cladribine","Vemurafenib + rituximab","Pentostatin","Ibrutinib","Rituximab monotherapy","Splenectomy","Interferon-alpha","Bendamustine + rituximab","Venetoclax","Observation"],correctIndex:1,rationale:"For relapsed classical HCL (BRAF V600E+), vemurafenib + rituximab achieves CR >85% and MRD negativity. This targeted combination is preferred over repeat purine analogue for more durable responses.",topic:"HCL relapse",difficulty:"hard"},
{id:"ce5",type:"emq",stem:"A 60-year-old woman with lymphocytosis. CLL score 2/5. Cytogenetics: t(11;14). Cyclin D1+, SOX11+. CT: generalised lymphadenopathy with largest mesenteric node 4 cm. Most likely diagnosis?",options:["CLL","Non-nodal leukaemic MCL","Classical (nodal) MCL","HCL","SMZL","Follicular lymphoma","LPL/WM","SDRPL","DLBCL","Prolymphocytic leukaemia"],correctIndex:2,rationale:"CLL score 2/5, t(11;14), Cyclin D1+, SOX11+ with significant lymphadenopathy = classical nodal MCL. Non-nodal leukaemic MCL would be SOX11\u2212, CD200+, without significant nodes.",topic:"MCL subtyping",difficulty:"hard"},
{id:"ce6",type:"emq",stem:"A 48-year-old woman with CLL (unmutated IGHV, TP53 mutated, complex karyotype) completed venetoclax + obinutuzumab achieving uMRD CR. Relapsed 18 months after stopping. Fit, no comorbidities. Most appropriate next step?",options:["Re-treat venetoclax + obinutuzumab","BTKi (ibrutinib or zanubrutinib)","FCR","Allo-HSCT directly","Chlorambucil + obinutuzumab","Rituximab monotherapy","CAR-T cell therapy","Observation","Bendamustine-rituximab","Radiotherapy"],correctIndex:1,rationale:"After venetoclax first-line, class-switch to BTKi is standard. Especially in high-risk (TP53/complex karyotype) patients, sequential therapy approach is preferred. Allo-HSCT may be considered later if both classes exhausted.",topic:"Sequential therapy",difficulty:"hard"},
{id:"ce7",type:"emq",stem:"A 67-year-old man with CLL on ibrutinib 18 months develops easy bruising, epistaxis, large subcutaneous haematoma after minor trauma. Platelets 165 \u00d7 10\u2079/L, PT and APTT normal. No anticoagulants used. Most likely explanation?",options:["Immune thrombocytopenia","Ibrutinib-related platelet dysfunction","von Willebrand disease","DIC","Acquired haemophilia","Vitamin K deficiency","Liver failure","TTP","HIT","Factor XIII deficiency"],correctIndex:1,rationale:"Ibrutinib inhibits BTK and TEC family kinases in platelets, impairing collagen-mediated aggregation causing qualitative defect independent of count. Most common bleeding mechanism; avoid warfarin and dual antiplatelet therapy.",topic:"BTKi adverse effects",difficulty:"hard"},
{id:"ce8",type:"emq",stem:"A 63-year-old woman: WBC 12 \u00d7 10\u2079/L with cleaved nuclei (centrocytes/centroblasts). Flow: CD19+, CD10+, BCL6+, CD5\u2212, CD23 weak. FISH: t(14;18)(q32;q21). BM biopsy: paratrabecular lymphoid aggregates. CT: widespread small lymphadenopathy. Diagnosis?",options:["CLL","SMZL","Classical HCL","Non-nodal leukaemic MCL","Follicular lymphoma (leukaemic phase)","LPL/WM","Prolymphocytic leukaemia","DLBCL","Burkitt lymphoma","SDRPL"],correctIndex:4,rationale:"CD10+, BCL6+, t(14;18), cleaved nuclei, paratrabecular marrow infiltration, CD5\u2212/CD23 weak = follicular lymphoma with leukaemic spillover. Paratrabecular pattern is characteristic (CLL is interstitial/diffuse).",topic:"Differential diagnosis",difficulty:"hard"},
{id:"ce9",type:"emq",stem:"A 70-year-old man with CLL (Binet A, mutated IGHV, no treatment) develops herpes zoster (two dermatomes). IgG 4.8 g/L. Two pneumonia episodes requiring hospitalisation in the past year. Most appropriate supportive measure?",options:["Prophylactic aciclovir only","Immunoglobulin replacement therapy","Start CLL-directed therapy","Pneumococcal vaccination only","Prophylactic co-trimoxazole","IV rituximab","Thalidomide","G-CSF prophylaxis","Tonsillectomy","No action needed"],correctIndex:1,rationale:"Symptomatic hypogammaglobulinaemia (IgG 4.8 g/L + recurrent serious infections) warrants IgG replacement (IVIg/SCIg). Target IgG trough >5 g/L. CLL therapy not indicated (Binet A, no active disease).",topic:"Supportive care",difficulty:"hard"},
{id:"ce10",type:"emq",stem:"A 76-year-old man with CLL (10 years, active surveillance, Binet A) has routine skin check revealing a 2 cm firm violaceous forearm nodule. Biopsy: Merkel cell carcinoma. CLL is stable. How should this be contextualised?",options:["Coincidental finding","CLL patients have substantially increased Merkel cell carcinoma risk","Merkel cell carcinoma causes CLL","Richter transformation as skin disease","CLL skin infiltration","Drug reaction from CLL therapy","Metastatic DLBCL to skin","Secondary MDS","EBV-related LPD","Squamous cell carcinoma misdiagnosed"],correctIndex:1,rationale:"CLL patients have 5\u201310 fold increased Merkel cell carcinoma risk due to chronic immune dysregulation. CLL has 10\u201315% rate of second malignancies. Requires standard oncological management independent of CLL.",topic:"Second malignancies",difficulty:"hard"}
]};

// === QUIZ ENGINE ===
let currentTab='mcq',attempt=null;
const letters='ABCDEFGHIJ';

function shuffle(arr){const a=[...arr];for(let i=a.length-1;i>0;i--){const j=Math.floor(Math.random()*(i+1));[a[i],a[j]]=[a[j],a[i]]}return a}

function buildAttempt(){
function shuffleQ(bank){return shuffle(bank.map(q=>{
const idx=q.options.map((_,i)=>i);const si=shuffle(idx);
return{...q,options:si.map(i=>q.options[i]),correctIndex:si.indexOf(q.correctIndex)};
}));}
return{id:crypto.randomUUID(),start:new Date().toISOString(),mcq:shuffleQ(QUIZ_BANK.mcq),emq:shuffleQ(QUIZ_BANK.emq),vmcq:shuffleQ(QUIZ_BANK.vmcq),vemq:shuffleQ(QUIZ_BANK.vemq),answers:{},finished:false};
}

function renderQuiz(){
const qs=attempt[currentTab];
const c=document.getElementById('quizContainer');
c.innerHTML='';
document.getElementById('resultsCard').classList.remove('show');
document.getElementById('finishBtn').style.display='inline-block';
qs.forEach((q,i)=>{
const div=document.createElement('div');div.className='q-card';div.id='q-'+q.id;
div.setAttribute('role','group');div.setAttribute('aria-label','Question '+(i+1));
const diffClass=q.difficulty==='easy'?'q-diff-easy':q.difficulty==='medium'?'q-diff-medium':'q-diff-hard';
div.innerHTML=`
<div class="q-meta"><span class="q-topic">${q.topic}</span><span class="${diffClass}">${q.difficulty}</span></div>
<div class="q-stem"><span class="mono" style="color:var(--teal);margin-right:6px">Q${i+1}.</span>${q.stem}</div>
<div class="q-options" role="radiogroup" aria-label="Answer options">${q.options.map((o,oi)=>`
<button class="q-opt" data-qid="${q.id}" data-oi="${oi}" onclick="selectAnswer('${q.id}',${oi})" role="radio" aria-checked="false" tabindex="0">
<span class="q-opt-letter">${letters[oi]}</span><span>${o}</span>
</button>`).join('')}</div>
<div class="q-feedback" id="fb-${q.id}"></div>`;
c.appendChild(div);
});
updateProgress();
}

function selectAnswer(qid,oi){
if(attempt.answers[qid]!==undefined)return;
attempt.answers[qid]=oi;
const qs=[...attempt.mcq,...attempt.emq,...attempt.vmcq,...attempt.vemq];
const q=qs.find(x=>x.id===qid);
const correct=oi===q.correctIndex;
const btns=document.querySelectorAll(`[data-qid="${qid}"]`);
btns.forEach(b=>{
b.classList.add('answered');
const boi=+b.dataset.oi;
if(boi===q.correctIndex)b.classList.add('correct');
if(boi===oi&&!correct)b.classList.add('incorrect');
b.setAttribute('aria-checked',boi===oi?'true':'false');
});
const fb=document.getElementById('fb-'+qid);
fb.className='q-feedback show '+(correct?'correct-fb':'incorrect-fb');
fb.innerHTML=`<strong>${correct?'Correct':'Incorrect'}</strong><br>${q.rationale}`;
updateProgress();
}

function updateProgress(){
const qs=attempt[currentTab];
const answered=qs.filter(q=>attempt.answers[q.id]!==undefined).length;
const pct=Math.round(answered/qs.length*100);
document.getElementById('progressBar').style.width=pct+'%';
if(answered===qs.length)document.getElementById('finishBtn').style.display='inline-block';
}

function switchTab(tab){
currentTab=tab;
document.getElementById('tabMCQ').classList.toggle('active',tab==='mcq');
document.getElementById('tabEMQ').classList.toggle('active',tab==='emq');
document.getElementById('tabVMCQ').classList.toggle('active',tab==='vmcq');
document.getElementById('tabVEMQ').classList.toggle('active',tab==='vemq');
renderQuiz();
}

function startEMQ(){switchTab('emq');document.getElementById('quiz-zone').scrollIntoView({behavior:'smooth'})}

function finishQuiz(){
attempt.finished=true;attempt.end=new Date().toISOString();
const mcqScore=calcScore(attempt.mcq);
const emqScore=calcScore(attempt.emq);
const vmcqScore=calcScore(attempt.vmcq);
const vemqScore=calcScore(attempt.vemq);
const total=mcqScore.correct+emqScore.correct+vmcqScore.correct+vemqScore.correct;
const totalQ=attempt.mcq.length+attempt.emq.length+attempt.vmcq.length+attempt.vemq.length;
const pct=Math.round(total/totalQ*100);
const mcqPct=Math.round(mcqScore.correct/attempt.mcq.length*100);
const emqPct=Math.round(emqScore.correct/attempt.emq.length*100);
const vmcqPct=Math.round(vmcqScore.correct/attempt.vmcq.length*100);
const vemqPct=Math.round(vemqScore.correct/attempt.vemq.length*100);

document.getElementById('resScore').textContent=pct+'%';
document.getElementById('resMCQ').textContent=mcqPct+'%';
document.getElementById('resEMQ').textContent=emqPct+'%';
document.getElementById('resVMCQ').textContent=vmcqPct+'%';
document.getElementById('resVEMQ').textContent=vemqPct+'%';
document.getElementById('resOverall').textContent=pct+'%';

let award='';
if(pct===100)award='You are CLL Master! üèÜüëë';
else if(pct>=90)award='Gold Medal! ü•á';
else if(pct>=80)award='Trophy! üèÜ';
else if(pct>=70)award='Pass ‚úì';
else award='Keep going!';
document.getElementById('resAward').textContent=award;

const gd=document.getElementById('resGuidance');
if(pct<70){
const domains={};
[...attempt.mcq,...attempt.emq,...attempt.vmcq,...attempt.vemq].forEach(q=>{
if(!domains[q.topic])domains[q.topic]={c:0,t:0};
domains[q.topic].t++;
if(attempt.answers[q.id]===q.correctIndex)domains[q.topic].c++;
});
const weak=Object.entries(domains).map(([t,s])=>({t,p:s.t?Math.round(s.c/s.t*100):0})).sort((a,b)=>a.p-b.p).slice(0,3);
gd.style.display='block';
gd.innerHTML=`<strong>You are building strong foundations.</strong> Focused revision will rapidly improve your score.<br><br><strong>Focus areas:</strong><ul>${weak.map(w=>`<li>${w.t} (${w.p}%)</li>`).join('')}</ul><br><em>Guidance from Dr Abdul Mannan</em>`;
}else{gd.style.display='none'}

document.getElementById('resultsCard').classList.add('show');
document.getElementById('finishBtn').style.display='none';
saveHistory({id:attempt.id,date:attempt.start,mcq:mcqPct,emq:emqPct,vmcq:vmcqPct,vemq:vemqPct,overall:pct,award});
document.getElementById('resultsCard').scrollIntoView({behavior:'smooth'});
}

function calcScore(qs){let c=0;qs.forEach(q=>{if(attempt.answers[q.id]===q.correctIndex)c++});return{correct:c,total:qs.length}}

function saveHistory(rec){
const k='cll_quiz_history';
const h=JSON.parse(localStorage.getItem(k)||'[]');
h.unshift(rec);
localStorage.setItem(k,JSON.stringify(h.slice(0,10)));
}

function resetQuiz(){attempt=buildAttempt();renderQuiz()}
function showAllQuestions(){document.getElementById('resultsCard').classList.remove('show');renderQuiz()}

function filterModules(val){
const v=val.toLowerCase();
document.querySelectorAll('.module').forEach(m=>{
m.style.display=m.textContent.toLowerCase().includes(v)?'':'none';
});
}

// INIT
attempt=buildAttempt();
renderQuiz();

// Sticky nav active state
const observer=new IntersectionObserver(entries=>{
entries.forEach(e=>{
if(e.isIntersecting){
document.querySelectorAll('.sticky-nav a').forEach(a=>a.classList.remove('active'));
const link=document.querySelector(`.sticky-nav a[href="#${e.target.id}"]`);
if(link)link.classList.add('active');
}
});
},{threshold:0.3});
document.querySelectorAll('.module,.quiz-zone').forEach(s=>observer.observe(s));
</script>
</body>
</html>
